COPE Advertising options


COGITO ERGO COPE ADVERTISING SPACE http://immunospot.com/index.php?id=233 Cell Sciences Inc

COPE Homepage Bottom of page Previous entry:
NK-cell receptor protein-2
Next entry:
NK-cell T-cell B-cell antigen
Random entry:
complement factor Bb
Search COPE:

Please donate

If you find COPE helpful,
please show your appreciation
by donating what you can afford.

NK-cells

[natural killer cells] These cells are being referred to also as large granular lymphocytes (abbr. LGL). For a subpopulation of NK-cells associated with the uterus see also: granulated metrial gland cells (GMG cells) and endometrial granulocytes (uterine NK-cells). For a subpopulation of non-cytolytic NK-cells with immunoregulatory functions see: NK-ireg cells. For a subset of NK-cells with features of memory cells see: Memory NK-cells.

NK-cells are innate immune cells involved in tumor surveillance, immunity against viruses, and IFN-gamma secretion (Colucci et al, 2003). NK-cells are cytotoxic lymphocytes that can lyse various types of target cells (tumor cells or virus-infected cells, for example) without prior sensitization. In addition, NK-cells are important sources of cytokines and chemokines. The term ANK-cells is used frequently to refer to NK-cells after cell activation by IL2. For a subpopulation of cytolytic T-lymphocytes with activities of NK-cells see: NK-CTL.

Based on the extent to which NK-cells express the marker CD56, two subpopulations can be distinguished (Ferlazzo, 2008; Robertson and Ritz, 1990; Poli et al, 2009; Cooper et al, 2001). CD56(dim) CD16(+) NK-cells (CD56(dim) CD16(bright) NK-cells) are predominant in peripheral blood, display potent cytolytic activity, and constitute the major subset (90 %). CD56(bright) NK-cells that are either CD16(+) or CD16(-) constitute a small percentage (5-10 %) of the circulating NK-cell population, predominate in tissues and secondary lymphoid organs, are poorly cytolytic, and appear to have mainly immunoregulatory functions (see: regulatory NK-cells). They are thought to be responsible for cytokine production, primarily IFN-gamma and TNF-alpha, in addition to other cytokines and chemokines (GM-CSF, CCL2, CCL3, CCL4, CCL5) (Caligiuri, 2008; Moretta et al, 2008; Fauriat et al, 2010). They constitutively express high affinity IL2 receptors and expand in vitro and in vivo in response to low (picomolar) doses of IL2 but do not themselves make IL2 (Caligiuri et al, 1990, 1993).

The cytolytic potential of NK-cells is either inhibited or activated by recognition of the major histocompatibility complex class I molecules on target cells. Target cell recognition involves a variety of C-type lectin proteins (Trinchieri et al, 1989; French and Yokoyama, 2003). NK-cell responses are activated or inhibited by recognizing HLA class I molecules on target cells. This is mediated by a great number of polymorphic killer immunoglobulin-like receptors (KIR family) expressed on NK-cells (for examples see: CD158).

NK-cells are bone marrow-derived cells and develop from CD34(+) hematopoietic stem cells. These stem cells give rise to common progenitors of lymphoid cells that then develop into bipotential progenitor cells with the capacity to develop into either NK-cells or T-cells. NK-cells develop from these common precursors. These precursors lose their capacity to develop into NK-cells after they have begun to rearrange the genes for the T-cell receptor (Spits et al, 1998). pre-NK-cells express only the marker CD161. Cells that express CD161 and CD56 are immature NK-cells. Mature NK-cells express CD161, CD56, and CD94 (Spits et al, 1998). Lytic pseudo-mature NK-cells have been defined as cells expressing markers of mature NK-cells (NK1.1 and DX5 in mice, CD56 in humans, CD94 / NKG2 receptors in both species) but not Ly49 receptors or KIR receptors (Williams et al, 1997; Sivori et al, 2002).

NK-cells can be differentiated from other cytotoxic lymphocytes such as MHC restricted cytotoxic T-lymphocytes (abbr. CTL), NK-like T-cells (MHC-unrestricted CTL), and NKT-cells by several criteria. They have a large granular lymphocyte morphology, do not express CD3, express CD56, display MHC-unrestricted cytotoxicity (i.e., they kill their target cells nonspecifically, and have a germ-line configuarion of the T-cell receptor genes (Trinchieri et al, 1989). Two types of peripheral blood NK-cells are distinguished by their expression of CD56: cells specializing in cytolysis are CD56(low). CD56(high) cells favor cytokine secretion (Cooper et al, 2001).

Most studies with NK-cells have been performed with cells obtained from human peripheral blood or mouse spleens. NK-cells are found also in other anatomical locations, including lung, intestine, lymph nodes, bone marrow and liver (see: pit cells). Cells from these locations may differ from NK-cells in the blood in terms of morphology and function and may display considerably different cell surface phenotypes and expression patterns (Cooper et al, 2001; Jonges et al, 2001; Vermijlen et al, 2004).

Peritt et al (1998) have reported that human NK-cells cultured in the presence of IL12 or IL4 differentiate into cell populations with the same cytotoxic activity but distinct patterns of cytokine secretion similar to Th1 cells and Th2 cells. NK1 cells are obtained when NK-cells are grown in IL12 in the presence of antibodies neutralizing IL4. These cells produce IL10 and IFN-gamma. NK2 cells are obtained when NK-cells are grown in IL4 in the presence of antibodies neutralizing IL12. These cells produce IL5 and IL13. Neither subset expresses IL2, IL4, IL14, IL15, or IL9. Similar findings have been reported by Deniz et al (2002).


NK-22 cells
constitute a subset of human NK-cells located in mucosa-associated lymphoid tissues, such as tonsils and Peyer's patches (Cella et al, 2009). These cells are characterized by expression of IL22, IL26, and LIF. NK-22 cells are triggered by acute exposure to IL23. In vitro, cytokines secreted by NK-22 cells stimulate epithelial cells to secrete IL10, proliferate and express a variety of mitogenic and anti-apoptotic molecules. NK-22 cells are found also in mouse mucosa-associated lymphoid tissues and appear in the small intestine lamina propria during bacterial infection, suggesting that NK-22 cells provide an innate source of IL22 that may help constrain inflammation and protect mucosal sites.


Hanna et al (2004) have reported expression profile comparisons of peripheral blood-derived CD56(dim) CD16(+), CD56(bright) CD16(-), and in vitro-activated CD16(+) NK-cells.

NK-cells have been shown to possess the capacity to express the proteins listed below. Please note the following general observations, which practically apply to all cell types: expression may be influenced by tissue localization, may occur only in discrete subpopulations of cells, may vary between established cell lines, primary cells, embryonic cells, mature cells, fully differentiated cells, activated cells, non-activated cells or growth conditions (confluent vs. sparse cultures), may be influenced by various disease states (including cancer environment), and may differ between species.
Note also: expression profile information lists entities only for which there is an entry in COPE or one of its subdictionaries.

The meaning of and is as follows: factor/protein is expressed; receptor (or, in some instances, binding sites) for this factor/protein is expressed. For further explanations concerning format, "hidden" information, and/or ambiguities see my remarks in the entry cell types.


4-1BB (CD137, CDw137, Ly63, lymphocyte antigen 63, ILA, induced by lymphocyte activation, TNFRSF9, TNF receptor superfamily member 9) (Wilcox et al, 2002; Lin et al, 2008)
4-1BB ligand (4-1BBL, TNFSF9, TNF ligand superfamily member 9, CD137L, CD137 ligand, Ly63 ligand) (Kashii et al, 1999)

ACTH (adrenocorticotropic hormone, corticotropin, POMC, proopiomelanocortin) receptors (melanocortin receptors) (Gatti et al, 1993)
adiponectin (Adpn, Apn, ACDC, adiponectin, C1q and collagen domain containing, ADIPOQ, apM1, adipose Most abundant gene transcript-1, GBP-28, gelatin-binding protein of 28 kDa, adipocyte complement related protein of 30 kDa, Acrp30, 30 kDa adipocyte complement-related protein, adipocyte-specific secretory protein) receptors (ADIPOR1, adiponectin receptor 1, PAQR1, progestin and adipoQ receptor family member 1, ACDCR1, TESBP1A, CGI-45, AURA43, augmented in rheumatoid arthritis 43) (Pang and Narendran, 2008)
adiponectin (Adpn, Apn, ACDC, adiponectin, C1q and collagen domain containing, ADIPOQ, apM1, adipose Most abundant gene transcript-1, GBP-28, gelatin-binding protein of 28 kDa, adipocyte complement related protein of 30 kDa, Acrp30, 30 kDa adipocyte complement-related protein, adipocyte-specific secretory protein) receptors (ADIPOR2, adiponectin receptor 2, PAQR2, progestin and adipoQ receptor family member 2, ACDCR2) (Pang and Narendran, 2008)
AIF-1 (Allograft inflammatory factor-1, daintain, MRF-1, microglial response factor-1, IBA-1, ionized calcium binding adaptor molecule-1, IRT-1, interferon response transcript 1) (Lund et al, 2007
Alpha-2-Macroglobulin (Alpha-2MG, Alpha-2M, A2M) (Lund et al, 2007)
alpha-MSH (melanocyte stimulating hormone-alpha, alpha-melanotropin, alpha-melanocortin, melanotropin, POMC, proopiomelanocortin) receptors (Neumann et al, 2001)
angiopoietin-2 (Ang-2, ANGPT2) (Li XF et al, 2001)
Annexin-1 (Annexin A1, ANX1, ANXA1, lipocortin-1, LPC1, LCT1, LC1, Lipo1, macrocortin, renocortin, lipomodulin, GIF, glycosylation inhibiting factor, CB9, chromobindin-9, calpactin-2) (Morand et al, 1995)
ARTS (apoptosis-related protein in the TGF-beta signaling pathway, SEPT4, septin 4, septin H5, M-septin, septin M, Bradeion, Brain protein H5, Bh5, Cerebral protein 7, CEP7, CDCREL-2, Cell division control-related protein 2, PNUTL-2, peanut-like-2) (Hall et al, 2005)
axl (ark, adhesion related kinase, tyro7, tyrosine-protein kinase 7, UFO, JTK11) (Caraux et al, 2006)
B7-H1 (B7 homolog-1, PDCD1L1, PDCD1 Ligand 1, PDL1, programmed death-1 ligand 1, CD274) (Saudemont et al, 2005)
B7-H3 (B7 homolog-3, B7RP-2, B7-related protein 2, B7-H3b, 2IgB7-H3, 4IgB7-H3, CD276) (Steinberger et al, 2004)
BASP1 (brain abundant membrane attached signal protein 1; brain acid-soluble protein 1, NAP-22, Neuron-enriched acidic protein 22kDa, 22 kDa neuronal tissue-enriched acidic protein, 9B1 antigen, CAP-23, cytoskeleton-associated protein 23) (Lund et al, 2007)
beta-Endorphin (POMC, proopiomelanocortin) receptors (Gatti et al, 1993; Wakao et al, 2000)
bFGF (basic fibroblast growth factor, FGF basic, FGF-2, Fibroblast growth factor-2, FGF-beta, Fibroblast growth factor-beta, HBGF-2, heparin binding growth factor-2) receptors (Lewis et al, 1991)

CCL1 (CC chemokine ligand 1, chemokine (C-C motif) ligand 1, SCYA1, I-309, TCA-3, T-cell activation-3, P500, SIS-epsilon) (Robertson, 2002)
CCL2 (CC chemokine ligand 2, chemokine (C-C motif) ligand 2, GDCF, Glioma-derived monocyte chemotactic factor-2, GDCF-2, HC11, JE, LDCF, MCAF, MCP, monocyte chemoattractant protein, MCP-1, monocyte chemoattractant protein-1, SMC-CF, smooth muscle cell chemotactic factor, TDCF, tumor-derived chemotactic factors, TSG-8, tumor necrosis factor-stimulated gene sequence-8, SCYA2) receptors (Al-Aoukaty et al, 1996; Allavena et al, 1996; Loetscher et al, 2000; Maghazachi et al, 1994; Morrison et al, 2003; Taub et al, 1995)
CCL3 (CC chemokine ligand 3, chemokine (C-C motif) ligand 3, MIP-1-alpha, macrophage inflammatory protein-1-alpha, 464.1, GOS-19-1, L2G25B, LD78, LD78-alpha, SCI, stem cell inhibition factor, stem cell inhibitor, TY5, SCYA3, SCYA3L1) (Bluman et al, 1996; Dorner et al, 2004; Fehniger et al, 1999; Mariani et al, 2002; Robertson, 2002; Sawaki et al, 2007)
CCL3 (CC chemokine ligand 3, chemokine (C-C motif) ligand 3, MIP-1-alpha, macrophage inflammatory protein-1-alpha, 464.1, GOS-19-1, L2G25B, LD78, LD78-alpha, SCI, stem cell inhibition factor, stem cell inhibitor, TY5, SCYA3, SCYA3L1) receptors (Al-Aoukaty et al, 1996; Loetscher et al, 2000; Maghazachi et al, 1994; Mariani et al, 2002; Taub et al, 1995)
CCL4 (CC chemokine ligand 4, chemokine (C-C motif) ligand 4, SCYA4, ACT-2, Immune activation gene-2, 744.1, G26, H400, HC21, Cytokine 21, human, LAG-1, lymphocyte activation gene-1, MIP-1-beta, macrophage inflammatory protein-1-beta, SIS-gamma) (Baixeras et al, 1990; Dorner et al, 2004; Fehniger et al, 1999; Robertson, 2002; Sawaki et al, 2007)
CCL4 (CC chemokine ligand 4, chemokine (C-C motif) ligand 4, SCYA4, ACT-2, Immune activation gene-2, 744.1, G26, H400, HC21, Cytokine 21, human, LAG-1, lymphocyte activation gene-1, MIP-1-beta, macrophage inflammatory protein-1-beta, SIS-gamma) receptors (Loetscher et al, 2000; Taub et al, 1995; Ottaviani et al, 2006)
CCL5 (CC chemokine ligand 5, chemokine (C-C motif) ligand 5, RANTES, EoCP-1, Eosinophil chemotactic polypeptide-1, SIS-delta, TCP228, T-cell-specific protein p228, SCYA5) (Dorner et al, 2004; Mariani et al, 2002; Robertson, 2002; Sawaki et al, 2007; Kumar et al, 2009)
CCL5 (CC chemokine ligand 5, chemokine (C-C motif) ligand 5, RANTES, EoCP-1, Eosinophil chemotactic polypeptide-1, SIS-delta, TCP228, T-cell-specific protein p228, SCYA5) receptors (Al-Aoukaty et al, 1996; Loetscher et al, 2000; Maghazachi et al, 1994; Mariani et al, 2002; Taub et al, 1995; Inngjerdingen et al, 1999; Ottaviani et al, 2006)
CCL7 (CC chemokine ligand 7, chemokine (C-C motif) ligand 7, SCYA7, MCP-3, monocyte chemoattractant protein-3, FIC, Fibroblast-inducible cytokine, NC28, MARC, mast cell activation-related chemokine) receptors (Allavena et al, 1996: Loetscher et al, 2000; Taub et al, 1995)
CCL8 (CC chemokine ligand 8, chemokine (C-C motif) ligand 8, SCYA8, MCP-2, monocyte monocyte chemoattractant protein-2, HC14, Cytokine 14, human) receptors (Allavena et al, 1996; Loetscher et al, 2000; Taub et al, 1995)
CCL15 (CC chemokine ligand 15, chemokine (C-C motif) ligand 15, HCC2, hemofiltrate CC-Chemokine-2, NCC3, new CC chemokine-3, MIP-5, macrophage inflammatory protein-5, Lkn-1, leukotactin-1, MIP-1-delta, macrophage inflammatory protein-1-delta, HMRP-2B, human MIP-related protein 2B, SCYL3, SCYA15) (Wang et al, 1998)
CCL19 (CC chemokine ligand 19, chemokine (C-C motif) ligand 19, ELC, EBI-1-Ligand Chemokine, Exodus-3, MIP-3-beta, macrophage inflammatory protein-3-beta, Ck-beta-11, Chemokine-beta-11, SCYA19) receptors (Al-Aloukaty et al, 1998)
CCL20 (CC chemokine ligand 20, chemokine (C-C motif) ligand 20, SCYA20, LARC, Liver and Activation Regulated Chemokine, Exodus, Exodus-1, MIP-3-alpha, macrophage inflammatory protein-3-alpha, Ck-beta-4, Chemokine-beta-4, ST38) receptors (Al-Aloukaty et al, 1998; Ottaviani et al, 2006)
CCL22 (CC chemokine ligand 22, chemokine (C-C motif) ligand 22, ABCD-1, DC/B-Ck, dendritic cell/B-cell derived chemokine, MDC, Human macrophage-derived chemokine STCP-1, stimulated T-cell chemotactic protein, SCYA22) (Andrew et al, 1998; Robertson, 2002)
CCL22 (CC chemokine ligand 22, chemokine (C-C motif) ligand 22, ABCD-1, DC/B-Ck, dendritic cell/B-cell derived chemokine, MDC, Human macrophage-derived chemokine STCP-1, stimulated T-cell chemotactic protein, SCYA22) receptors (Godiska et al, 1997; Inngjerdingen et al, 1999)
CCR1 (CC-Chemokine receptor 1, RANTES receptor, MIP-1-alpha receptor, LD78 receptor, CC-CKR1, HM145, YT4, CD191, CMKBR1, chemokine-beta receptor 1) (Inngjerdingen et al, 2001; Bernardini et al, 2008; Ottaviani et al, 2006)
CCR2 (CC-Chemokine receptor 2, CC-CKR2A, CCR2A, CC-CKR2B, CCR2B, MCP-1 receptor A, MCP-1 receptor B, CMKBR2, chemokine-beta receptor 2, CD192) (Hanna et al, 2005; Inngjerdingen et al, 2001; Polentarutti et al, 1997; Ottaviani et al, 2006)
CCR4 (CC-Chemokine receptor 4, CC-CKR4, CKR4, CMKBR4, chemokine-beta receptor 4, K5-5, CD194) (Inngjerdingen et al, 2000, 2001; Ottaviani et al, 2006)
CCR5 (CC-Chemokine receptor 5, CC-CKR5, CMKBR5, ChemR13, CD195) (Robertson, 2002; Vermijlen et al, 2004; Wang et al, 2004; Dybkaer et al, 2007; Ottaviani et al, 2006; Berahovich et al, 2006)
CCR6 (CC-Chemokine receptor 6, GPRCY4, STRL22, DRY6, CKR-L3, CMKBR6, chemokine-beta receptor 6, GPR29, CD196) (Ottaviani et al, 2006; Berahovich et al, 2006; Liu et al, 2005)
CCR7 (CC-Chemokine receptor 7, EBI-1, EBV induced gene-1, blr-2, CMKBR7, Burkitt lymphoma receptor-2, CD197) (Kim et al, 1999; Robertson, 2002; Berahovich et al, 2006; Dybkaer et al, 2007; Ottaviani et al, 2006; Bellora F et al, 2012)
CCR8 (CC-Chemokine receptor 8, TER1, CY6, ChemR1, CMKBR8, chemokine-beta receptor 8, CKR-L1 CDw198) (Inngjerdingen et al, 2000, 2001; Ottaviani et al, 2006)
CCR9 (CC-Chemokine receptor 9, GPR9-6, GPR28, G-protein-coupled receptor-28, CDw199) (Berahovich et al, 2006)
CD2 (T11, 35.1, M-T910, 9.6, OX34, Tp50, LFA-2, lymphocyte function-associated antigen-2, Leu5, Leu5b, Ly37, OKT11, SRBC receptor, sheep red blood cell receptor, sheep erythrocyte receptor, erythrocyte receptor, E-rosette receptor, Rosette receptor, HuLy-m1) (Bell et al, 1992; Bryceson et al, 2006; Sedlmayr et al, 1996; Ida and Anderson, 1998; Levitt et al, 1991; Menp et al, 1993; Moingeon P et al, 1992; Nagler et al, 1989; Perussia et al, 1985; Rabinowich et al, 1993)
CD4 (T4, Leu3, OKT4, L3T4, Ly4, W3/25, OX38, OX35) (Milush JM et al, 2009)
CD6 (OX52, T12, TP120) (Braun et al, 2011)
CD7 (gp40, HuLy-m2, Leu9, Tp41) (Nagler et al, 1989; Lyman et al, 2000; Rabinowich et al, 1994; Milush JM et al, 2009)
CD8 (T8, Leu2, Lyt2, OKT8, CD8-alpha, CD8a, Ly2, OX8, CD8-beta, CD8b, Lyt3, Ly3) (Dalle et al, 2005)
CD9 (602-29 antigen, ALB6 antigen, BA2, BTCC-1, DRAP-27, Diphtheria toxin receptor associated protein 27 kDa, GIG2, MIC3, MRP-1, Motility-related protein-1, NCA, neural cell surface antigen, p24, SH-9, TSPAN29, tetraspanin 29) (Eriksson et al, 2004; Lund et al, 2007)
CD11a (ITGAL, integrin-alpha-L, LFA-1, Ly15, Ly21, LFA-1, lymphocyte function-associated antigen-1, LFA-1-alpha, lymphocyte function-associated antigen-1-alpha, neutrophil adherence receptor alpha-M subunit, OND(a), OND) (Allavena et al, 1997; Aramburu et al, 1990, 1993; Bendall et al, 1995; Frey et al, 1998; Schallhammer et al, 1997; Menp et al, 1993; Melder et al, 1991; Rabinowich et al, 1993; Wing et al, 1996; Franitza et al, 2004)
CD11b (CR3, CR3a, complement receptor-3, C3bi receptor, ITGAM, integrin-alpha-M, HNA4a, human neutrophil antigen 4a, MART, MART(a), Mo1, Ly40, Mac-1, OKM1, OX42, VIM12) (DeHart et al, 2005; Menp et al, 1993; Nagler et al, 1989; Schallhammer et al, 1997; Perussia et al, 1985; Schleicher et al, 2005)
CD11c (CR4, complement receptor-4, iC3b receptor, ITGAX, integrin-alpha-X, Leu M5, myeloid membrane antigen, OX42, p150,95) (Kamath et al, 2005; Menp et al, 1993; Melder et al, 1991; Nagler et al, 1989; Sedlmayr et al, 1996; Schallhammer et al, 1997; Schleicher et al, 2005)
CD14 (endotoxin receptor, Leu M3, LPS-R, Mo2, MY4, myeloid cell-specific leucine-rich glycoprotein, hdl, heedless) (Sawaki et al, 2007)
CD15s (CD15, 3-FAL, 3-Fucosyl-N-Acetyllactosamine, 3-FL, 3-Fucosyl-lactosamine, 80H.5, AGF 4.48, C3D-1, DAKO-M1, ELFT, ELAM-1 ligand fucosyltransferase, FAL, Fucosyl-N-Acetyllactosamine, 3-alpha-fucosyl-N-acetyl-lactosamine, FCT3A, alpha-3-fucosyltransferase, FUC-T-IV, fucosyltransferase 4, FUT-4, fucosyltransferase 4, LeuM1, LeX, Lewis X, X-hapten, hapten X, X-determinant, LNF-3, lacto-N-fucopentaose 3, LNFP-3, Lacto-N-Fucopentose 3 ceramide, MMA, My-1, myeloid-associated surface antigen, PMN7, polymorphonuclear leukocyte antigen 7, SSEA-1, stage-specific embryonic antigen-1) (Sedlmayr et al, 1996; Schallhammer et al, 1997)
CD16 (hFcRIII, Fc-gamma R3, FCGR3A, FCGR3, Neutrophil antigen NA, HNA1, human neutrophil antigen 1, Leu11, VEP13, B73.1, 31D8, N901) (Anegon et al, 1988; Arancia et al, 1986; Arase et al, 2001; Azzoni et al, 1995; Balboa et al, 1992; Barakonyi et al, 2004; Borrego et al, 1994; Bryceson et al, 2006; Choi et al, 2004; Cosentino and Cathcart, 1987; Deaglio et al, 2002; Eriksson et al, 2004; Galandrini et al, 1996; Jewett et al, 2006; Lanier et al, 1989; Manara et al, 1986; Manoussaka et al, 1997; Mori et al, 1998; Perussia et al, 1985; Sulica et al, 1996; Warren and Kinnear, 1999; Wing et al, 1996; Xu and Chong, 1996; Fan et al, 2008; Neves et al, 2009; Bonanno et al, 2009)
CD18 (ITGB2, integrin-beta-2, 2E6, AURA46, augmented in rheumatoid arthritis 46) (Bendall et al, 1995; DeHart et al, 2005; Menp et al, 1993; Melder et al, 1991; Schallhammer et al, 1997; Nagler et al, 1989; Wing et al, 1996)
CD26 (1F7, 2B9, 5F8, ACT-3, ADABP, ADA binding protein, ADCP2, adenosine deaminase complexing protein 2, BT5/9, DPCR1, DPP4, dipeptidyl peptidase 4, HAM.4, intestinal dipeptidyl peptidase, EC3.4.14.5, OX61, TA1, TA5/9, THAM, thymocyte-activating molecule, TP103, WC10 antigen, FAP-beta, Fibroblast activation protein-beta) (Buhling et al, 1994; Yamabe et al, 1997)
CD27 (1A4, Tp55, T14, S152, TNFRSF7, TNF receptor superfamily member 7) (Orengo et al, 1997; Sugita et al, 1992; Fan et al, 2008)
CD27 ligand (CD27L, CD27LG, CD70, Ki-24, TNFSF7, TNF ligand superfamily member 7) (Kashii et al, 1999)
CD28 (T90/44, Tp44, Kolt-2) (Cheung et al, 1999; Galea-Lauri et al, 1999; Nandi et al, 1994)
CD28 (T90/44, Tp44, Kolt-2) receptors (Walker et al, 1999)
CD29 (FNRB, fibronectin receptor beta chain, ITGB1, integrin-beta-1, platelet protein GPIIa, VLA-beta, very late activation antigen-beta, VLA-beta-1, VLA-4 beta subunit) (Schallhammer et al, 1997; Bendall et al, 1995; Menp et al, 1993)
CD30 (Ki-1, Ki-2, R4-4, Ber H2 antigen, TNFRSF8, TNF receptor superfamily member 8) (Cambiaggi et al, 1993)
CD30 ligand (CD30L, CD153, TNFSF8, TNF ligand superfamily member 8) (Kashii et al, 1999)
CD32 (hFcRII, Fc-gamma R2, FCG2, FCGR2, CD32a, CD32b, FCGR2A, Fc-gamma R2a, FCGR2B, Fc-gamma R2b, IGFR2, immunoglobulin G Fc receptor 2) (Ernst et al, 2002; Manoussaka et al, 1997)
CD33 (CD33M, CD33m, MY9, SIGLEC-3, sialic acid binding immunoglobulin-like lectin 3) (Handgretinger et al, 1993; Hernndez-Caselles T et al, 2006)
CD38 (ADP-ribosyl cyclase, ADP-ribosyl cyclase-1, cyclic ADP-ribose hydrolase, ecto-NAD+ glycohydrolase, Ecto-nicotinamide adenine dinucleotide glycohydrolase, EC3.2.2.5, Leu17, OKT10, T10) (Deaglio et al, 2002; Mallone et al, 2001; Nagler et al, 1989; Perussia et al, 1985; Sconocchia et al, 1999; Neves et al, 2009)
CD39 (apyrase, ATPDase, ATP diphosphohydrolase, EC3.6.1.5, Ecto-Apyrase, Ecto-ATPase, ENTPD1, ectonucleoside triphosphate diphosphohydrolase 1, NTPDase-1, vascular ATP diphosphohydrolase, G28-8, Bgp95) (Koziak et al, 1999; Vermijlen et al, 2004; Kansas et al, 1991; Gouttefangeas et al, 1992)
CD40 ligand (CD40L, CD40LG, TRAP, TNF-related activation protein, CD154, 5c8, gp39, Ly62, T-BAM, IMD3, TNFSF5, TNF ligand superfamily member 5) (Jyothi and Khar, 2000)
CD43 (3E8 antigen, GALGP, galactoglycoprotein, gpL115, L60, Leu22, Lp-3, LSN, leukosialin, Ly48, MT1, OX75, S7 antigen, SPN, sialophorin, W3/13) (Schallhammer et al, 1997; Aguado et al, 1999; DeHart et al, 2005)
CD44 (CDw44, CD44H, CD44A, CD44s, CD44st, CD44std, AnWj blood group antigen, ECMR-3, extracellular matrix receptor-3, class 3 ECMR, gp85, HCAM, homing-associated cell adhesion molecule, Hermes-1, Hermes antigen, HUTCH-1, Indian blood group antigen, In blood group antigen, Ly24, MC56, MDU2, MDU3, MIC4, MUC 2-63, OX49, PGP1, PGP1.1, phagocytic glycoprotein-1, GM35 antigen) (Galandrini et al, 1996; Schallhammer et al, 1997; Sedlmayr et al, 1996; Menp et al, 1993; McKallip et al, 2005; Nagler et al, 1989; Rafi-Janajreh et al, 1998; Sague et al, 2004; Sconocchia et al, 1994)
CD45 (B220, HuLy-m4, LCA, leukocyte common antigen, Ly5, OX1, OX22, OX30, PTPRC, protein tyrosine phosphatase receptor type C, EC3.1.3.4, T200) (DeHart et al, 2005; Shen et al, 1995; Xu and Chong, 1995; Zaroukian et al, 1986)
CD45R (2H4, 6B2, Lp220, 4KB5) (Nagler et al, 1989)
CD45RA (OX33, B220, HuLy-m4, LCA, leukocyte common antigen, Ly5, OX1, OX22, OX30, PTPRC, protein tyrosine phosphatase receptor type C, EC3.1.3.4, T200) (Schallhammer et al, 1997; Fan et al, 2008)
CD45R0 (UCHL-1, B220, HuLy-m4, LCA, leukocyte common antigen, Ly5, OX1, OX22, OX30, PTPRC, protein tyrosine phosphatase receptor type C, EC3.1.3.4, T200) (Schallhammer et al, 1997; Sedlmayr et al, 1996)
CD48 (17D6, 5-8A10, 6.28, BCM1, B-cell activation marker 1, BLAST, B-LAST 1, Blast-1, HM48-1, Ly-m3, HuLy-m3, MEM-102, OX45, OX46, OX78, sgp-60, SLAMF2, signaling lymphocyte activation molecule family member 2, SLAM family member 2, TCT.1, T-cell target 1) (Assarsson et al, 2004; Lee KM et al, 2006)
CD49b (Br alloantigen, DX5, ECMR-2, extracellular matrix receptor-2, GPIa, HPA-5, human platelet antigen-5, ITGA2, integrin-alpha-2, platelet glycoprotein Ia/IIa, VLA-2, very late activation antigen 2, VLAA2, VLA2 receptor alpha 2 subunit, Zav alloantigen) (Arase et al, 2001;Rabinowich et al, 1993)
CD49c (CSAT antigen band 2 protein, FRP-2, fusion regulatory protein-2, GAP-B3, galactoprotein B3, ITGA3, integrin-alpha-3, MSK18, VLA-3, very late activation antigen 3, ECMR-1, Extracellular matrix receptor-1, class 1 ECMR, VLA-alpha 3, very late activation antigen alpha-3, VLAA3, VLA-3 receptor alpha 3 subunit) (Rabinowich et al, 1993)
CD49d (ITGA4, integrin-alpha-4, VLA-4, very late activation antigen 4, VLAA4, VLA4 receptor alpha 4 subunit, VLA-alpha 4, very late activation antigen alpha-4) (Allavena et al, 1997; Bendall et al, 1995; Franitza et al, 2004; Rabinowich et al, 1993)
CD49e (fibronectin receptor alpha chain, FNRA, ITGA5, integrin-alpha-5, ECMR-6, Extracellular matrix receptor-6, class 6 ECMR, GPIc, platelet glycoprotein Ic, VLA-alpha 5, very late activation antigen alpha-5, VLA-5, very late activation antigen 5, VLA-5-alpha) (Bendall et al, 1995; Sedlmayr et al, 1996; Rabinowich et al, 1993)
CD49f (ITGA6, integrin-alpha-6, platelet gpI, VLA-6, very late activation antigen 6, VLA-6 alpha chain, VLA-alpha 6, very late activation antigen alpha-6, GPIc*, platelet glycoprotein Ic*) (Bendall et al, 1995; Sedlmayr et al, 1996; Rabinowich et al, 1993)
CD51 (ITGAV, integrin-alpha-V, L230, MSK8 vitronectin receptor VNRA, vitronectin receptor alpha subunit) (DeHart et al, 2005; Rabinowich et al, 1995)
CD54 (7F7, BB2, human rhinovirus receptor, ICAM-1, intercellular adhesion molecule 1, IFN-gamma regulated human melanoma-associated antigen, Ly47, MALA-2, Me14-D12, P3.58) (Dalle et al, 2005; Lin and Yan, 2000; Lin et al, 2003; Lyman et al, 2000; Menp et al, 1993; Rabinowich et al, 1993)
CD55 (CD55a, CD55b, complement decay-accelerating factor, decay-accelerating factor, DAF, DAF-GPI, DAF-TM, GPI-DAF, TM-DAF, DAF1, decay-accelerating factor 1, DAF2, decay-accelerating factor 2, Cromer blood group antigen) (Sedlmayr et al, 1996; Solomon et al, 1995)
CD56 (5.1.H11, BASCA, brain-associated small cell lung cancer antigen, Leu19, MSK39, NCAM, neural cell adhesion molecule, NCAM1, neural cell adhesion molecule-1, NCAM-120, neural cell adhesion molecule-120, NCAM-140, neural cell adhesion molecule-140, NCAM-180, neural cell adhesion molecule-180, NKH-1, PSA-NCAM, polysialylated NCAM, E-NCAM, embryonic NCAM, embryonic neural cell adhesion molecule) (Barakonyi et al, 2004; Choi et al, 2004; Cooper et al, 2001; Dalbeth et al, 2004; Dalle et al, 2005; Eriksson et al, 2004; Schallhammer et al, 1997; Eriksson et al, 2004; Fehniger et al, 2003; Frey et al, 1998; Jacobs et al, 2001; Melder et al, 1991; Fan et al, 2008; Berahovich et al, 2006; Milush JM et al, 2009; Bonanno et al, 2009)
CD57 (HNK-1, human natural killer-1, Leu7, NK-1, GlcAT-P, glucuronosyltransferase P, B3GAT1, beta-1,3-glucuronyltransferase 1, Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1, UDP-GlcUA:glycoprotein beta-1,3-glucuronyltransferase) (Abo and Balch, 1983; Dalle et al, 2005; Nagler et al, 1989; Perussia et al, 1985; Vassiliadou and Bulmer, 1996)
CD58 (LFA-3, lymphocyte function-associated antigen-3, T11TS, T11 target structure) (Menp et al, 1993; Rabinowich et al, 1993)
CD59 (CD59a, protectin, MIC11, MIN2, MIN3, MSK21, HRF20, homologous restriction factor-20 kDa, MACIF, membrane attack complex inhibitory factor, MAC-IP, MAC-inhibitory protein, H19, MIRL, membrane inhibitor of reactive lysis, P18, 1F5, 16.3A5, BRIC 229, YTH 53.1) (Marcenario et al, 2003; Solomon et al, 1995)
CD61 (CD61A, F4, F11, GPIIb/IIIa, HPA-1, human platelet antigen-1, HPA-4, human platelet antigen-4, ITGB3, integrin-beta-3, Pen alloantigen, Pen(a), Pen(b), PL(A1), platelet fibrinogen receptor beta subunit, platelet glycoprotein IIIa, GP3A, Yuk alloantigen, Yuk(a), Yuk(b), Zw alloantigen, Zw(a), Zw(b)) (Menp et al, 1993)
CD62L (gp90-MEL, LAM-1, leukocyte adhesion molecule 1, LECAM-1, leukocyte adhesion molecule 1, Leu8, LSEL, L-selectin, selectin-L, SELL, LYAM1, MEL-14, OX85, PLNHR, TQ-1) (Frey et al, 1998; Lin et al, 2003; L-selectin) (Schallhammer et al, 1997; Dalle et al, 2005; Menp et al, 1993; Sedlmayr et al, 1996; Mocellin et al, 2004; Nagler et al, 1989; Juelke K et al, 2010)
CD63 (81H, AD1, GP55, granulophysin, HOP-26, LIMP, lysosomal integral membrane protein, LIMP-1, lysosomal integral membrane protein-1, ME491, melanoma associated antigen ME491, MLA1, melanoma-associated antigen 1, NGA, neuroglandular antigen, NKI-C3, OMA81H, ocular melanoma-associated antigen 81H, PLTGP40, platelet glycoprotein gp40, TSPAN30, tetraspanin 30) (Vermijlen et al, 2004)
CD65 (Ceramide dodecasaccharide, VIM-2) (Sedlmayr et al, 1996)
CD66 (CD66a, BGP, biliary glycoprotein, BGP-1, biliary glycoprotein 1, CEACAM-1, CEA-related cell adhesion molecule 1, CCAM, cell-cell adhesion molecule, CEACAMPS, NCA-160, nonspecific crossreacting antigen 160) (Markel et al, 2002)
CD68 (EBM11, gp110, Ki-M6, Ki-M7, KP-1, macrosialin, microsialin, PG-M1, PM-1k, SCARD1, scavenger receptor class D member 1, Y1/82A, Y2/131) (Strobl et al, 1995; Hameed et al, 1994)
CD69 (AIM, activation inducer molecule, BL-AC/P26, CLEC2C, C-type lectin domain family 2 member C, EA1, early antigen 1, early T-cell activation antigen p60, gp34/28, Leu23, MLR3, VEA) (Borrego et al, 1993; Clausen et al, 2003; d'Ettorre et al, 2006; Gerosa et al, 1992; Lyman et al, 2000; Gerosa et al, 1993; Lin et al, 2000; Rabinowich et al, 1993; Prado-Drayer et al, 2008; Neves et al, 2009; Lund H et al, 2012)
CD72 (CD72a, CD72b, CD72c, Lyb2, Ly19, Ly19.2, Ly32, Ly32.2) (Alcon et al, 2009)
CD81 (2F7, 5A6, S5.7, TAPA-1, target of antiproliferative antibody 1, TSPAN28, tetraspanin 28) (Crotta et al, 2002)
CD84 (CDw84, Ly9b, lymphocyte antigen 9b, lymphocyte antigen 9-beta, Ly9-beta, MAX.3 antigen, SLAMF5, signaling lymphocyte activation molecule family member 5, SLAM family member 5) (Sintes et al, 2010)
CD85a (CD85, LILRB3, leukocyte immunoglobulin-like receptor subfamily B member 3, ILT5, immunoglobulin-like transcript 5, LIR3, leukocyte immunoglobulin-like receptor 3, HL9, Monocyte inhibitory receptor HL9, PIRB, paired immunoglobulin-like receptor B) (Arm et al, 1997)
CD85c (LILRB5, leukocyte immunoglobulin-like receptor subfamily B member 5, LIR8, leukocyte immunoglobulin-like receptor 8) (Borges et al, 1997)
CD85d (LILRB2, leukocyte immunoglobulin-like receptor subfamily B member 2, ILT4, immunoglobulin-like transcript 4, LIR2, leukocyte immunoglobulin-like receptor 2, MIR10, monocyte/macrophage immunoglobulin-like receptor 10) (Colonna et al, 1997; LeMaoult et al, 2005)
CD85e (LILRA3, leukocyte immunoglobulin-like receptor subfamily A member 3, ILT6, immunoglobulin-like transcript 6, LIR4, leukocyte immunoglobulin-like receptor 4, HM43/HM31, Monocyte inhibitory receptor HM43/HM31, HM43, HM31) (Borges et al, 1997)
CD85j (ILT2, immunoglobulin-like transcript 2, LIR1, leukocyte immunoglobulin-like receptor 1, MIR7, monocyte/macrophage immunoglobulin-like receptor 7, LILRB1, leukocyte immunoglobulin-like receptor subfamily B member 1) (Banham et al, 1999; LeMaoult et al, 2005)
CD85k (LILRB4, leukocyte immunoglobulin-like receptor subfamily B member 4, ILT3, immunoglobulin-like transcript 3, LIR5, leukocyte immunoglobulin-like receptor 5, HM18, Monocyte inhibitory receptor HM18, gp49B, gp49B1, gp49B2) (Borges et al, 1997; LeMaoult et al, 2005; Gu et al, 2003; Wang et al, 2000)
CD87 (MO3, PLAUR, plasminogen activator urokinase receptor, UPA-R, urokinase plasminogen activator receptor, URKR, urokinase receptor) (Al-Atrash et al, 2000; Nykjaer et al, 1992)
CD93 (AA4, C1q receptor, C1qR1, C1qRp, collectin receptor, GR11, Ly68, MXRA4) (Dean et al, 2000, 2001; Lovik et al, 2000)
CD94 (KP43, KLRD1, killer cell lectin-like receptor subfamily D member 1, CD94C) (Aramburu et al, 1990, 1993; Balboa et al, 1992; Briard et al, 2002; DeHart et al, 2005; Eriksson et al, 2004; Fraser et al, 2002; Ida et al, 1997; Jacobs et al, 2001; Jewett et al, 2006; Jinushi et al, 2004; Mingari et al, 1997; Moser et al, 2002; Perez-Villar et al, 1995; Vermijlen et al, 2004; Voss et al, 1998; Wilhelm et al, 2003; Briard et al, 2002; Saez-Borderias et al, 2009; Wang et al, 2007; Petersen L et al, 2009; Bonanno et al, 2009; Lieto et al, 2003)
CD95 (FAS, APO-1, apoptosis antigen-1, APT1, TNFRSF6, TNF receptor superfamily member 6, FASTM, FASL receptor) (Medvedev et al, 1997; Fan et al, 2008)
CD96 (TACTILE, TH-111 antigen) (Wang et al, 1992; Fuchs et al, 2004; El-Sherbiny et al, 2007)
CD97 (BL-KDD/F12, GR1, TM7LN1, AURA51, augmented in rheumatoid arthritis 51) (Kop et al, 2009)
CD98 (CD98LC, 4F2lc, 4F2, 4F2hc, FRP-1, fusion regulatory protein-1, LAT1, system-L amino acid transporter 1, L-type amino acid transporter 1, Ly10, Ly-m10, MDU1, MPE16, membrane protein E16, RL-388, SLC3A2, solute carrier family 3 member 2, SLC7A5, solute carrier family 7 member 5) (Dybkaer et al, 2007)
CD107a (LAMP-1, lysosome-associated membrane glycoprotein-1, LAMPA, lysosome-associated membrane glycoprotein A, LGP120, lysosomal glycoprotein 120) (Giustiniani et al, 2009)
CD152 (CTLA-4, cytotoxic T-lymphocyte associated antigen 4, Ly56) (Vermijlen et al, 2004)
CD158a (p58.1, p50.1, NKAT1, NK-associated transcript-1, EB6, KIR2DL1, Killer cell immunoglobulin-like receptor 2DL1, KIR-K6, CL42) (Jacobs et al, 2001; Kogure et al, 2002; Miller and McCullar, 2001; Fan et al, 2008; Bonanno et al, 2009)
CD158b (p58.2, p50.2, GL183, KIR2DL2, Killer cell immunoglobulin-like receptor 2DL2) (Jacobs et al, 2001; Kogure et al, 2002; Miller and McCullar, 2001; Bonanno et al, 2009)
CD158d (KIR2DL4, Killer cell immunoglobulin-like receptor 2DL4, KIR-103AS, Killer cell inhibitory receptor 103AS) (Kikuchi-Maki et al, 2003; Rajagopalan et al, 2001; LeMaoult et al, 2005; Li et al, 2009)
CD158h (KIR2DS1, Killer cell immunoglobulin-like receptor 2DS1) (Cognet et al, 2010)
CD159a (NKG2, NKG2A, natural killer cell lectin-like receptor 2A, NKG2B, natural killer cell lectin-like receptor 2B, NK cell receptor A, C-lectin type 2 protein, KLRC1, killer cell lectin-like receptor subfamily C member 1) (Fraser et al, 2002; Gays et al, 2005; Mori et al, 1998; Wang et al, 2007; Dybkaer et al, 2007)
CD160 (BY55, NK1, NK28) (Barakonyi et al, 2004; Le Bouteiller et al, 2002; Giustiniani et al, 2007; Giustiniani et al, 2009)
CD161 (CLEC5B, C-type lectin domain family 5 member B, KLRB1, killer cell lectin-like receptor subfamily B member 1, NKR-P1A, CD161a) (Al-Aoukaty et al, 1997; Arase et al, 1996; Dalle et al, 2005; Giorda et al, 1990; Jacobs et al, 2001; Ljutic et al, 2005; Poggi et al, 1998; Bonanno et al, 2009; Kulkarni et al, 2012; Montaldo E et al, 2012)
CD161c (NK1.1, NKR-P1C, natural killer cell receptor P1C; NK-cell receptor P1C, NKR-P1.9, Ly55) (Asea and Stein-Streilein, 1998; DeHart et al, 2005; Hirsh et al, 2004; Karlhofer and Yokoyama, 1991; Manoussaka et al, 1997)
CD226 (DNAM-1, DNAX accessory molecule 1, PTA1, platelet and T-cell activation antigen 1, TLiSA1, T lineage-specific activation antigen 1) (Bryceson et al, 2006; Shibuya et al, 1996; Jia et al, 2000; Burns et al, 1985; El-Sherbiny et al, 2007; Dybkaer et al, 2007; Seth et al, 2009)
CD229 (hly9, HumLy9, Lgp100, Ly9, SLAMF3, signaling lymphocyte activation molecule family member 3, T100 (Sintes et al, 2007)
CD244 (2B4, 2B4-S, 2B4-L, C1.7, C9.1, Ly90, NAIL, NK-cell activation-inducing ligand, NKR2B4, natural killer cell receptor 2B4, NK-cell receptor 2B4, Nmrk, Non-MHC restricted killing associated, p38, SLAMF4, signaling lymphocyte activation molecule family member 4) (Bryceson et al, 2006; Chuang et al, 2001, 2003; Johnson et al, 2000, 2003; Kubin et al, 1999; Kubota et al, 2003; Manoussaka et al, 1997; Romero et al, 2004; Burgess SJ et al, 2006; Bonanno et al, 2009; Gao N et al, 2006; Stark and Watzl, 2006; Kim JR et al, 2010; Sun C et al, 2012)
CD252 (CD134 ligand, CD134L, gp34, OX40 ligand, OX40L, TNFSF4, TNF ligand superfamily member 4, TXGP1, tax-transcriptionally activated glycoprotein 1) (Kashii et al, 1999; Zingoni et al, 2004)
CD296 (ADP ribosyltransferase 1, ART1, ADP ribosyltransferase 2, ART2, EC2.4.2.31, RT6) (Wonigeit et al, 1997)
CD300A (CMRF35H, CMRF35H9, IGSF12, immunoglobulin superfamily member 12, IRC1, IRC2, IRp60, Inhibitory receptor protein 60, MAIR-I, myeloid-associated immunoglobulin-like receptor I, CLM8, CMRF35-like molecule-8, LMIR1, leukocyte mono-Ig-like receptor 1) (Green et al, 1998;Lankry et al, 2010)
CD300B (CD300LB, CD300 molecule-like family member B, CLM7, CMRF35-like molecule-7, CMRF35-like molecule-7, IREM3, immune receptor expressed by myeloid cells 3, TREM5, triggering receptor expressed on myeloid cells 5, MAIR-VII, myeloid-associated immunoglobulin-like receptor VII, LMIR5, leukocyte mono-Ig-like receptor 5) (Martinez-Barriocanal and Sayos, 2006)
CD300C (CMRF35, CMRF35A, CMRF35A1, IGSF16, immunoglobulin superfamily member 16, LIR, MAIR-III, myeloid-associated immunoglobulin-like receptor III, CLM6, CMRF35-like molecule-6) (Daish et al, 1993; Lankry et al, 2011)
CD317 (120G8 antigen, BST-2, bone marrow stromal cell antigen-2, PDCA-1, plasmacytoid dendritic cell antigen-1, Tetherin, HM1.24 antigen) (Blasius et al, 2006)
CD319 (19A, 19A24, CRACC, CD2-like receptor activating cytotoxic cells, CS1, FOAP-12, Novel Ly9, SLAMF7, SLAM family member 7) (Boles and Mathew, 2001; Tassi and Colonna, 2005; Stark and Watzl, 2006)
CD335 (Ly94, MAR-1, Mouse-activating receptor 1, NKp46, NCR1, natural cytotoxicity receptor 1, RAR-1, rat-activating receptor 1) (Briard et al, 2002; Bryceson et al, 2006; Vankayalapati et al, 2002; Vermijlen et al, 2004; Triplett et al, 2009; Bozzano et al, 2009; Bonanno et al, 2009)
CD336 (Ly95, NCR2, natural cytotoxicity receptor 2; NKp44) (Briard et al, 2002; Vitale et al, 1998; de Rham et al, 2007; De Maria et al, 2009; Triplett et al, 2009)
CD337 (1C7, B144, LST1, leukocyte-specific transcript 1, Ly117, NCR3, natural cytotoxicity receptor 3, NKp30, Natural killer cell p30-related protein) (Burgess SJ et al, 2006; Briard et al, 2002; Ferlazzo et al, 2002; Bozzano et al, 2009)
ceruloplasmin (Cp, ferroxidase, Fe(II) - oxygen oxidoreductase, iron (II) - oxygen oxidoreductase, EC1.16.3.1, Ran-2 antigen, rat neural antigen-2, PACAP(1-38) binding factor, pituitary adenylate cyclase-activating polypeptide1-38-binding factor) (Banha et al, 2008)
Chemerin (RARRES2, retinoic acid receptor responder 2, tazarotene-induced gene-2, TIG2) receptors (ChemerinR, ChemR23, chemokine receptor 23, CMKLR1, chemokine-like receptor 1, Dez) (Luangsay S et al, 2009)
Clusterin (CLU, dimeric acidic glycoprotein, DAG protein, testosterone repressed prostate message-2, TRPM-2, sulfated glycoprotein-2, SGP-2, complement-associated protein SP-40,40, SP-40,40, complement lysis inhibitor, CLI, Apolipoprotein J) (Vermijlen et al, 2004)
Clusterin (CLU, dimeric acidic glycoprotein, DAG protein, testosterone repressed prostate message-2, TRPM-2, sulfated glycoprotein-2, SGP-2, complement-associated protein SP-40,40, SP-40,40, complement lysis inhibitor, CLI, Apolipoprotein J) receptors (Sonn et al, 2010)
common gamma (IL2RG, IL2 receptor-gamma, interleukin-2 receptor-gamma, gammac, gamma common, common cytokine receptor-gamma, cytokine receptor common subunit gamma, CD132, IMD4, immunodeficiency 4, SCIDX, X-linked severe combined immunodeficiency, SCIDX1, X-linked severe combined immunodeficiency, SCIDX1, X-linked severe combined immunodeficiency-1, XSCID, X-linked severe combined immunodeficiency) (CD132) (Joshi et al, 2001)
complement receptor-3 (CD11b CD18) (Muto et al, 1993)
CRP (C-reactive protein, PTX1, pentraxin-1, PCBP, phosphorylcholine-binding protein) (Bray et al, 1988)
CRTAM (cytotoxic and regulatory T cell molecule, Class-I MHC-restricted T-cell-associated molecule, CD355) (Steigerwald et al 2009; Boles et al, 2005)
CX3CL1 (fractalkine, FKN, FK, CX3C membrane-anchored chemokine, C3Xkine, neurotactin, NTT, NTN, ABCD-3, SCYD1) receptors (CX3CR1, V28, CMKBRL1, chemokine beta receptor-like-1, GPR13, G-protein-coupled receptor-13) (Al-Aloukaty et al, 1998; Berahovich et al, 2006; Dybkaer et al, 2007; Huang et al, 2006; Infante-Duarte et al, 2005; Inngjerdingen et al, 2001; Nishimura et al, 2002; Ottaviani et al, 2006; Patel et al, 2008; Robertson, 2002; Robinson et al, 2003; Sechler et al, 2004; Yoneda et al, 2000, 2003; Zhang et al, 2006)
CXCL1 (CXC chemokine ligand 1, chemokine (C-X-C motif) ligand 1, SCYB1, CINC-1, Cytokine induced neutrophil chemoattractant-1, fsp, fibroblast secretory protein, GRO1, GRO-alpha, KC, MGSA, melanoma growth stimulatory activity, MGSA-alpha, melanoma growth stimulatory activity-alpha, NAP-3, neutrophil-activating protein-3, N51) (Vermijlen et al, 2004)
CXCL2 (CXC chemokine ligand 2, chemokine (C-X-C motif) ligand 2, CINC-2-alpha, Cytokine induced neutrophil chemoattractant-2-alpha, GRO2, growth-related oncogene-2, GRO-beta, growth regulated oncogene-beta, MIP-2-alpha, macrophage inflammatory protein-2-alpha, MGSA-beta, melanoma growth stimulatory activity-beta, SCYB2) (Vermijlen et al, 2004)
CXCL4 (CXC chemokine ligand 4, chemokine (C-X-C motif) ligand 4, PF4, platelet factor-4, Endothelial cell growth inhibitor, Heparin neutralizing protein, Megakaryocyte-stimulatory-factor, Oncostatin A, SCYB4) receptors (Marti et al, 2002)
CXCL9 (CXC chemokine ligand 9, chemokine (C-X-C motif) ligand 9, mig, monokine induced by gamma-Interferon, Humig, Mumig, CRG-10, cytokine responsive gene-10, M119, SCYB9) receptors (Saudemont et al, 2005)
CXCL10 (CXC chemokine ligand 10, chemokine (C-X-C motif) ligand 10, IP-10, INP-10, inflammatory protein 10, Interferon-inducible protein-10, IFN-inducible protein 10, immune protein-10; 10 kDa interferon-inducible protein, gamma-IP-10, CRG-2, cytokine responsive gene-2, C7, Ifi10, interferon-inducible-10, mob-1, SCYB10) (Pisegna et al, 2004)
CXCL10 (CXC chemokine ligand 10, chemokine (C-X-C motif) ligand 10, IP-10, INP-10, inflammatory protein 10, Interferon-inducible protein-10, IFN-inducible protein 10, immune protein-10; 10 kDa interferon-inducible protein, gamma-IP-10, CRG-2, cytokine responsive gene-2, C7, Ifi10, interferon-inducible-10, mob-1, SCYB10) receptors (Maghazachi et al, 1997; Taub et al, 1995; Inngjerdingen et al, 2003; Saudemont et al, 2005; Vermijlen et al, 2004; Ottaviani et al, 2006)
CXCL11 (CXC chemokine ligand 11, chemokine (C-X-C motif) ligand 11, H174, beta-R1, I-TAC, Interferon-inducible T-cell alpha chemoattractant, IP-9, interferon-gamma-inducible protein-9, SCYB11, SCYB9B) receptors (Saudemont et al, 2005)
CXCL12 (CXC chemokine ligand 12, chemokine (C-X-C motif) ligand 12, IRH, intercrine reduced in hepatomas, hIRH, intercrine reduced in hepatomas, SDF-1-alpha, CXCL12-alpha, SDF-1-beta, CXCL12-beta, SDF, SDF-1, Stromal cell-derived factor, Stromal cell-derived factor-1-alpha, Stromal cell-derived factor-1-beta, PBSF, pre-B-cell growth stimulating factor, TLSF, Thymic lymphoma cell stimulating factor, Thymic lymphoma cell stimulating factor-alpha, Thymic lymphoma cell stimulating factor-beta, TLSF-alpha, TLSF-beta, TPAR-1, TPA repressed gene-1, SCYB12) (Mselle et al, 2009)
CXCL12 (CXC chemokine ligand 12, chemokine (C-X-C motif) ligand 12, IRH, intercrine reduced in hepatomas, hIRH, intercrine reduced in hepatomas, SDF-1-alpha, CXCL12-alpha, SDF-1-beta, CXCL12-beta, SDF, SDF-1, Stromal cell-derived factor, Stromal cell-derived factor-1-alpha, Stromal cell-derived factor-1-beta, PBSF, pre-B-cell growth stimulating factor, TLSF, Thymic lymphoma cell stimulating factor, Thymic lymphoma cell stimulating factor-alpha, Thymic lymphoma cell stimulating factor-beta, TLSF-alpha, TLSF-beta, TPAR-1, TPA repressed gene-1, SCYB12) receptors (Inngjerdingen et al, 1999; Hanna et al, 2003; Inngjerdingen et al, 2003; Saudemont et al, 2005)
CXCR3 (CXCR3A, CXC-Chemokine receptor 3, IP-10 receptor, Mig receptor, CKR-L2, GPR9, CD183) (Hodge et al, 2002; Petkovic et al, 2004; Wang et al, 2004; Robertson, 2002; Bernardini et al, 2008; Berahovich et al, 2006; Ottaviani et al, 2006; Liu et al, 2005)
CXCR4 (CXC-Chemokine receptor 4, LESTR, leukocyte-derived 7-transmembrane domain receptor, HUMSTR, NPYRL, neuropeptide Y receptor-like, NPY3R, neuropeptide Y receptor Y3, HM89, Fusin, LCR-1, FB22, LAP3, Lipopolysaccharide-associated protein 3, SDF-1 receptor, CD184, AURA86, augmented in rheumatoid arthritis 86) (Franitza et al, 2004; Robertson, 2002; Bernardini et al, 2008; Berahovich et al, 2006)
CXCR5 (MDR15, monocyte-derived receptor 15, blr-1, Burkitt lymphoma receptor-1, CD185) (Berahovich et al, 2006)
CXCR6 (CXC-Chemokine receptor 6, TYMSTR, T-lymphocyte-expressed seven-transmembrane domain receptor, Bonzo, STRL33, CD186) (Wang et al, 2004; Berahovich et al, 2006)
Cystatin F (Cystatin-7, CST7, CMAP, cystatin-like metastasis-associated protein, leukocystatin) (Halfon et al, 1998)

Defensins (Agerberth et al, 2000)
Defensins (Alpha-Defensins) (Chalifour et al, 2004; Obata-Onai et al, 2002; Vermijlen et al, 2004)
DEK receptors (Mor-Vaknin et al, 2006)

FAS ligand (FASL, FASLG, APT1LG1, apoptosis antigen ligand 1, CD95 ligand, CD95L, APO-1 ligand, APTL, Apoptosis antigen ligand, TNF ligand superfamily member 6, TNFSF6, CD178) (Kashii et al, 1999; Medvedev et al, 1997; Dybkaer et al, 2007)
FCRL3 (Fc receptor-like-3, FCRH3, Fc receptor homolog 3, IRTA3, Immune receptor translocation-associated protein 3, SPAP2, SH2 domain-containing phosphatase anchor protein 2, IFGP3, IFGP family protein 3, CD307c) (Polson et al, 2006)
follistatin (FST, Follicle stimulating hormone suppressing protein, FSP, Activin-binding protein) (Vermijlen et al, 2004)
FPR1 (formyl peptide receptor-1, fMLP receptor, FRP, N-formyl peptide receptor, formyl peptide receptor) (Kim SD et al, 2009; Mocellin et al, 2004)
FPRL1 (formyl peptide receptor-like-1, FPRH1, formyl peptide receptor homolog-1, FPR2, formyl peptide receptor-2, lipoxin A4 receptor, ALXR, LXA4R, HM63) (Kim SD et al, 2009)
FPRL2 (formyl peptide receptor-like-2, FPR-like-2, FPRH2, formyl peptide receptor homolog-2, FPR3, formyl peptide receptor-3) (Kim SD et al, 2009)

Galectin-1 (Gal-1, LGALS1, galactose-specific soluble lectin 1, L-14-I, Lactose-binding lectin 1, S-lac lectin-1, Galaptin, 14 kDa beta-galactoside-binding lectin, 14 kDa lectin, HLBP14, 14 kDa laminin binding protein) (Kollr et al, 2012; Kopcow et al, 2008; Molvarec et al, 2011; Koopman et al, 2003; Hanna et al, 2004)
Galectin-1 (Gal-1, LGALS1, galactose-specific soluble lectin 1, L-14-I, Lactose-binding lectin 1, S-lac lectin-1, Galaptin, 14 kDa beta-galactoside-binding lectin, 14 kDa lectin, HLBP14, 14 kDa laminin binding protein) receptors (Cedeno-Laurent F et al, 2012)
Galectin-2 (Hanna et al, 2004)
galectin-3 (Gal-3, LGALS3, galactose-specific soluble lectin 3, Mac-2, macrophage galactose-specific lectin-2, L-29, CBP-35, carbohydrate binding protein-35, IgE binding factor epsilon, Epsilon BP) (Crider-Pirkle S et al, 2002; Hanna et al, 2004)
Galectin-4 (Gal-4, LGALS4, galactose-specific soluble lectin 4, lectin galactoside-binding soluble 4, L-36, L-36LBP, Lactose-binding lectin 4, NY-CO-27 antigen) (Hanna et al, 2004)
Galectin-7 (Hanna et al, 2004)
Galectin-8 (Gal-8, LGALS8, galactose-specific soluble lectin 8, PCTA1, Prostate carcinoma tumor antigen 1, Po66-CBP, Po66 carbohydrate-binding protein) (Hanna et al, 2004)
Galectin-9 (LGALS9, galactose-specific soluble lectin 9, Ecalectin, UAT, urate transporter, Tim-3L, Tim-3 ligand) (Hanna et al, 2004)
galectin-12 (Gal-12, LGALS12, galactose-specific soluble lectin 12; lectin, galactoside-binding, soluble, 12, GRIP1, Galectin-related inhibitor of proliferation) (Hanna et al, 2004)
G-CSF (Granulocyte colony stimulating factor, CSF-3, colony stimulating factor-3, CSF-beta, colony stimulating factor-beta, G-CSA, granulocytic neutrophil colony stimulating activity, Pluripoietin-beta) (Saito et al, 1993)
GM-CSF (Granulocyte-macrophage colony stimulating factor, BPA, burst promoting activity, CSF-2, colony stimulating factor-2, GM-CSA, Granulocyte-macrophage colony stimulating activity, MGI-1GM, macrophage-granulocyte inducer, Pluripoietin-alpha) (Aste-Amezaga et al, 1994; Cuturi et al, 1989; De Sanctis et al, 1997; Fehniger et al, 1999; Blanchard et al, 1991; Kim and Yokoyama, 1998; Levitt et al, 1991; Manoussaka et al, 1997; Naume et al, 1993; Saito et al, 1993; Steigerwald et al 2009)
granulysin (T-cell activation gene 519, T-lymphocyte activation gene 519, TLA519, 519, NKG5, Perforin-enhancing protein, PEPr) (Chung et al, 2008; Obata-Onai et al, 2002)
Granzyme A (GZMA, granzyme 1, Hanukah factor, H factor, HFSP, Hanukah factor serine protease, CTLA-3, cytotoxic T-lymphocyte-associated serine esterase 3, SE-1, serine esterase-1, TSP-1, MTSP-1, T-cell-derived serine proteinase-1, HuTSP, Human T-cell specific proteinase) (DeBlaker-Hohe et al, 1995; Grossman et al, 2004; Loetscher et al, 1996; Mori et al, 1998; Salcedo et al, 1993; Sayers et al, 2001; Trotta et al, 2008; Velotti et al, 1989; Zhang et al, 2008; Bratke et al, 2005; Bade et al, 2005)
Granzyme B (GZMB, Granzyme 2, serine protease B, SE-2, serine esterase-2, CSP-B, cytotoxic serine protease B, CCP1, cytotoxic cell protease-1, Asp-ase, CGL1, cathepsin G-like-1, CTLA-1, cytotoxic T-lymphocyte-associated serine esterase-1, fragmentin-2, RNKP1, rat natural killer protease-1) (Clement et al, 1990; Dalle et al, 2005; DeBlaker-Hohe et al, 1995; DeHart et al, 2005; Fan et al, 2008; Grossman et al, 2004; Mori et al, 1998; Obata-Onai et al, 2002; Prakash et al, 2009; Salcedo et al, 1993; Sedelies et al, 2004; Trotta et al, 2008; Wakao et al, 2000; Zhang et al, 2008; Bratke et al, 2005)
Granzyme H (GZMH, CSP-C, cytotoxic serine protease C, CGL2, cathepsin G-like-2) (MacIvor et al, 1999; Sedelies et al, 2004; Fellows et al, 2007; Hou et al, 2008; Romero et al, 2009; Zhang et al, 2008)
Granzyme K (GZMK, granzyme 3, tryptase-2, fragmentin-3) (Guo et al, 2008; Zhang et al, 2008; Bratke et al, 2005; Bade et al, 2005)
Granzyme M (GZMM, Met-ase, Lymphocyte Met-ase 1, Natural killer cell Met-ase) (Sayers et al, 2001; Krenacs et al, 2003; Bovenschen et al, 2008; Cullen et al, 2009; Kelly et al, 2004; Bade et al, 2005)
growth hormone (GH, Somatotropic hormone, Somatotropin, GH1, growth hormone 1, GHN, growth hormone normal) receptors (Bidlingmaier et al, 1997)

HLA-G (Human leukocyte antigen G, HLA-6.0, HLA60, Qa) receptors (KIR2DL4) (Li et al, 2009)
HMG-1 (high mobility group protein-1, HMGB1, high mobility group box-1, amphoterin, DEF, Differentiation enhancing factor, Neurite growth-promoting protein, SBP-1, Sulfoglucuronyl carbohydrate binding protein-1) (Mocellin et al, 2004)
hsp70 (heat shock protein 70) receptors (Gastpar et al, 2004; Multhoff et al, 1999)

IFN-alpha (interferon-alpha, Alpha-Interferon, aIFN, B-cell interferon, Leukocyte interferon, LeIFN, Lymphoblast interferon, LyIFN-alpha) receptors (IFNAR1, IFN-alpha/beta receptor 1, interferon (alpha, beta and omega) receptor 1, IFN-alphaR1, IFRC, IFNAR, IFNAR2, IFN-alpha/beta receptor 2, interferon (alpha, beta and omega) receptor 2, IFN-alphaR2, IFNABR) (Frey et al, 1998; Hunter et al, 1997; Jewett and Bonavida, 1995; Liang et al, 2003; Zhang et al, 2008; Yamamoto et al, 2004)
IFN-beta (Beta-Interferon, Interferon-beta, bIFN, Fibroblast interferon, Fi-IFN, F-IFN) receptors (IFNAR1, IFN-alpha/beta receptor 1, interferon (alpha, beta and omega) receptor 1, IFN-alphaR1, IFRC, IFNAR, IFNAR2, IFN-alpha/beta receptor 2, interferon (alpha, beta and omega) receptor 2, IFN-alphaR2, IFNABR) (Hunter et al, 1997)
IFN-gamma (IFNG, interferon-gamma, Gamma-Interferon, gIFN) (Arase et al, 1996; Aste-Amezaga et al, 1994; Barakonyi et al, 2004; Bream et al, 2003; Cai et al, 1999; Cheung et al, 1999; De Sanctis et al, 1997; d'Ettorre et al, 2006; Deniz et al, 1999; Dorner et al, 2004; Eriksson et al, 2004; Handa et al, 1983; Hayashi et al, 2003; Hunter et al, 1995; Hunter et al, 1997; Kim and Yokoyama, 1998; Lewis et al, 1991; Lidstrom et al, 2003; Mori et al, 1998; Naume et al, 1993; Saito et al, 1993; Spaggiari et al, 2003; Todd et al, 2001; Kamath et al, 2005; Sawaki et al, 2007; Smithgall et al, 2008; Steigerwald et al 2009; Bellora F et al, 2012; Lund H et al, 2012)
IFN-gamma (IFNG, interferon-gamma, Gamma-Interferon, gIFN) receptors (IFNGR1, IFN-gamma receptor-1, IFN-gamma-R1, interferon-gamma receptor 1, immune interferon receptor 1, AVP type 2, antiviral protein type 2, CD119, IFNGR2, interferon-gamma receptor 2, IFN-gamma receptor 2, IFN-gamma-R2, IFGR2, IFNGT1, interferon-gamma transducer 1) (Bohn and Autenrieth, 2000)
IGF-1 (Insulin-like growth factor-1, Erythropoietic factor, mechano growth factor, MGF, ILGF1, somatomedin C, NSILA, non-suppressible insulin-like activity, Somatomedin A, Somatomedin C, sulfation factor, Mecasermin) receptors (IGF1R, CD221, JTK13) (Auernhammer et al, 1996; Bidlingmaier et al, 1997)
IGFBP10 (Insulin-like growth factor binding protein-10, IGF binding protein-10, cyr-61, Cysteine-rich angiogenic inducer 61, cysteine-rich 61, CCN1) receptors (Zhang X et al, 2012)
IGSF8 (immunoglobulin superfamily member 8, CD81P3, CD81 partner 3, EWI-2, EWI motif-containing protein 2, KASP, KAI1/CD82-associated surface protein, KCT-4, Keratinocytes associated transmembrane protein 4, PGRL, prostaglandin regulatory like, CD316) (Charrin et al, 2003)
IL1 (interleukin-1) (Galli et al, 1990)
IL1-alpha (IL1A, interleukin-1-alpha, IL1F1, Interleukin-1 family member 1, BAF, B-cell activating factor, BCAF, B-cell activating factor, EP, endogenous pyrogens, LAF, lymphocyte activating factor, LEM, leukocyte endogenous mediator, MCF, mononuclear cell factor, MNCF, mononuclear cell factor, MP, mitogenic protein, TRF-3, T-cell replacing factor-3, Tumor inhibitory factor-2) (De Sanctis et al, 1997)
IL1-beta (IL1B, interleukin-1-beta, IL1F2, Interleukin-1 family member 2, Catabolin, H1, Hematopoietin-1, IFN-beta inducing factor, Interleukin-beta, OAF, osteoclast activating factor) (De Sanctis et al, 1997; Mori et al, 1998)
IL1 (interleukin-1) receptors (IL1RA, IL1R-alpha, IL1 receptor-alpha; interleukin-1 receptor-alpha, IL1R1, IL1 receptor type 1, Interleukin-1 receptor 1, IL1 receptor R1, CD121a; IL1RB, IL1R-beta, IL1 receptor-beta; interleukin-1 receptor-beta, IL1R2, IL1 receptor type 2, Interleukin-1 receptor 2, IL1 receptor R2, CD121b, AURA31, augmented in rheumatoid arthritis 31) (Bluman et al, 1996; Cooper et al, 2001; Copnti et al, 1991; Hunter et al, 1995; Shirakawa et al, 1986; Vermijlen et al, 2004)
IL2 (Interleukin-2, BF, blastogenic factor, EDF, eosinophil differentiation factor, KHF, killer cell helper factor, LMF, lymphocyte mitogenic factor, LPF, lymphocyte proliferation factor, MAF-C I, macrophage-activating factor for cytotoxicity I, PFC-EA, plaque forming cell enhancing factor, SCIF, secondary cytotoxic T-cell inducing factor, TCGF, T-cell growth factor, TCPA, T colony-promoting activity, TDF, thymocyte differentiation factor, T-LPF, T-lymphocyte promotor factor, TMF, thymocyte mitogenic factor, T-cell maturation factor, T-cell mitogenic factor, TRF-3, T-cell replacing factor-3, TSF, thymocyte stimulating factor) (De Sanctis et al, 1997; Manoussaka et al, 1997)
IL2 (Interleukin-2, BF, blastogenic factor, EDF, eosinophil differentiation factor, KHF, killer cell helper factor, LMF, lymphocyte mitogenic factor, LPF, lymphocyte proliferation factor, MAF-C I, macrophage-activating factor for cytotoxicity I, PFC-EA, plaque forming cell enhancing factor, SCIF, secondary cytotoxic T-cell inducing factor, TCGF, T-cell growth factor, TCPA, T colony-promoting activity, TDF, thymocyte differentiation factor, T-LPF, T-lymphocyte promotor factor, TMF, thymocyte mitogenic factor, T-cell maturation factor, T-cell mitogenic factor, TRF-3, T-cell replacing factor-3, TSF, thymocyte stimulating factor) receptors (IL2RA, interleukin-2 receptor-alpha; IL2R-alpha; IL2 receptor-alpha, IL2R, interleukin-2 receptor, TAC antigen, TCGFR, T-cell growth factor receptor, IDDM10, insulin-dependent diabetes mellitus 10, CD25; Ly43, lymphocyte antigen 43, OX39, IL2RB, interleukin-2 receptor-beta; IL2R-beta; IL2 receptor-beta, CD122; IL2RG, IL2 receptor-gamma, interleukin-2 receptor-gamma, IL2R-gamma, common gamma, gammac, gamma common, common cytokine receptor-gamma; cytokine receptor common subunit gamma, CD132, SCIDX1, X-linked severe combined immunodeficiency-1) (Anegon et al, 1988; Arbour et al, 1996; Armant et al, 1995; Baume et al, 1992; Biron et al, 1990; Bonnema et al, 1994; Bosse and Ades, 1992; Bream et al, 2003; Clausen et al, 2003; Frey et al, 1998; Lyman et al, 2000; Gays et al, 2005; Grund et al, 2005; Handa et al, 1983; Nagler et al, 1989; Naume et al, 1993; Perussia et al, 1985; Rabinowich et al, 1993; Saito et al, 1996; Tomizawa et al, 1992; Vermijlen et al, 2004; Voss et al, 1992; Zhang et al, 2008; de Rham et al, 2007)
IL3 (Interleukin-3, 20-alpha-hydroxysteroid dehydrogenase inducing factor, BPA, burst promoting activity, CFU-S, colony-forming unit spleen, CSF-2-alpha, colony stimulating factor-2-alpha, CSF-2-beta, colony stimulating factor-2-beta, ECSF, erythroid colony stimulating factor, Eo-CSF, eosinophil colony stimulating factor, HCGF, Hematopoietic cell growth factor, HP2, Hematopoietin-2, HPGF, hematopoietic cell growth factor, MCGF, mast cell growth factor, MCSA, multi-colony stimulating activity, Meg-CSF, megakaryocyte colony stimulating factor, MGF, mast cell growth factor, Mixed colony stimulating factor, Multi-CSF, Multi-colony stimulating factor, multi-HGF, multilineage hemopoietic growth factor, Multipoietin, NC cell growth factor, natural cytotoxic cell growth factor, Neutrophil-granulocyte colony stimulating factor, PSF, progenitor stimulating factor, PSH, panspecific hemopoietin, SAF, stem cell activating factor, Thy1 inducing factor) (Cuturi et al, 1989; Manoussaka et al, 1997)
IL4 (Interleukin-4, BCDF-epsilon, B-cell differentiation factor-epsilon, BCDF-gamma, B-cell differentiation factor-gamma, BCGF-gamma, B-cell growth factor-gamma, BCGF-1, B-cell growth factor-1, Binetrakin, BSF-1, B-cell stimulating factor-1, BSF-p1, B-cell stimulating factor p1, EL4-BCGF, EL4 B-cell growth factor, HCGF, Hodgkin's cell growth factor, IgE-EF, IgE enhancing factor, IgG1-enhancing factor, IgG1-induction factor, LMW-BCGF, low molecular weight B-cell growth factor, MaGEF, Mast cell growth enhancing factor, MCGF-2, mast cell growth factor-2, MFF, macrophage fusion factor, Pitrakinra, TCGF-2, T-cell growth factor-2) (Deniz et al, 1999; Lidstrom et al, 2003; Lorenzen et al, 2000; Todd et al, 2001; Vermijlen et al, 2004)
IL4 (Interleukin-4, BCDF-epsilon, B-cell differentiation factor-epsilon, BCDF-gamma, B-cell differentiation factor-gamma, BCGF-gamma, B-cell growth factor-gamma, BCGF-1, B-cell growth factor-1, Binetrakin, BSF-1, B-cell stimulating factor-1, BSF-p1, B-cell stimulating factor p1, EL4-BCGF, EL4 B-cell growth factor, HCGF, Hodgkin's cell growth factor, IgE-EF, IgE enhancing factor, IgG1-enhancing factor, IgG1-induction factor, LMW-BCGF, low molecular weight B-cell growth factor, MaGEF, Mast cell growth enhancing factor, MCGF-2, mast cell growth factor-2, MFF, macrophage fusion factor, Pitrakinra, TCGF-2, T-cell growth factor-2) receptors (IL4RA, IL4R-alpha, interleukin-4 receptor-alpha, IL4R, interleukin-4 receptor, CD124) (Bosse and Ades, 1992; Bream et al, 2003; Deniz et al, 1999; Gays et al, 2005; Hayakawa et al, 1991; Lewis et al, 1991; Loza et al, 2002; Marcenaro et al, 2005; Nagler et al, 1988; Saito et al, 1996; Tomizawa et al, 1992; Warren et al, 1995)
IL5 (Interleukin-5, B151-TRF, B151 T-cell replacing factor, BCDF, B-cell differentiation factors, BCDF-alpha, B-cell differentiation factor-alpha, BCDF-mu, B-cell differentiation factor-mu, BCGF-2, B-cell growth factor-2, DL-BCGF, Dennert line B-cell growth factor, BGDF, B-cell growth and differentiation factor, CFU-Eo GSF, colony-forming unit eosinophil growth stimulating factor, EDF, eosinophil differentiation factor, Eo-CSF, Eosinophil colony stimulating factor, Eo-DF, eosinophil differentiation factor, ESP, eosinophil stimulation promoter, IgA-EF, IgA enhancing factor, KHF, killer helper factor, TRF-1, T-cell replacing factor-1) (Deniz et al, 1999; Walker et al, 1998; Warren et al, 1995)
IL6 (interleukin-6, 26 kDa protein, BSF-2, B-cell stimulating factor-2, CDF, CAT development factor, choline acetyltransferase development factor, Cytolytic differentiation factor for T-lymphocytes, FDGI, fibroblast-derived growth inhibitor, hybridoma growth factor, HPGF, hybridoma/plasmacytoma growth factor, HSF, hepatocyte stimulating factor, HSF-1, hepatocyte stimulating factor-1, ILHP1, Interleukin-hemopoietin-1, MGI-2A, Macrophage-granulocyte inducer-2A, Myeloma GF, myeloma growth factor, NKAF, natural killer cell activating factor, TAF, T-cell activating factor, Thymocyte growth factor, TSF, thymocyte stimulating factor) (Avanzi et al, 1989; Barakonyi et al, 2004; Li et al, 2009)
IL6 (interleukin-6, 26 kDa protein, BSF-2, B-cell stimulating factor-2, CDF, CAT development factor, choline acetyltransferase development factor, Cytolytic differentiation factor for T-lymphocytes, FDGI, fibroblast-derived growth inhibitor, hybridoma growth factor, HPGF, hybridoma/plasmacytoma growth factor, HSF, hepatocyte stimulating factor, HSF-1, hepatocyte stimulating factor-1, ILHP1, Interleukin-hemopoietin-1, MGI-2A, Macrophage-granulocyte inducer-2A, Myeloma GF, myeloma growth factor, NKAF, natural killer cell activating factor, TAF, T-cell activating factor, Thymocyte growth factor, TSF, thymocyte stimulating factor) receptors (IL6RA, IL6R-alpha, IL6R, interleukin-6 receptor, interleukin-6 receptor-alpha, CD126, IL6ST, IL6 signal transducer, interleukin-6 signal transducer, IL6R-beta, interleukin-6 receptor-beta, IL6RB, CDw130, CD130) (Lewis et al, 1991; Luger et al, 1989; Rabinowich et al, 1993)
IL7 (Interleukin-7, B-cell precursor growth-promoting activity, Lpo-1, lymphopoietin-1, LP-1, PBGF, Pre-B-cell growth factor, serum factor from patients with ulcerative colitis, Thymocyte growth factor) receptors (IL7R, IL7RA, IL7R-alpha, interleukin-7 receptor, interleukin-7 receptor-alpha; CD127, CDw127) (Armant et al, 1995; Lum et al, 2004; Naume et al, 1993; Toren et al, 1997; Zhang J et al, 2012)
IL8 (interleukin-8, SCYB8, 3-10C, 9E3, ANAP, anionic neutrophil-activating peptide, Chemotaxin, CEF-4, CT/IL8, CXCL8, CXC chemokine ligand 8, chemokine (C-X-C motif) ligand 8, EDNAP, endothelial-derived neutrophil-activating peptide, EMF-1, embryo fibroblast protein 1, Emoctakin, ENAP, Endothelial cell neutrophil-activating peptide, FDNAP, Fibroblast-derived neutrophil-activating peptide, FINAP, fibroblast-derived neutrophil-activating protein, GCF, granulocyte chemotactic factor, GCP, granulocyte chemotactic peptide, LAI, leukocyte adhesion inhibitor, LCF, lymphocyte chemotactic factors, LDNAP, leukocyte-derived neutrophil-activating peptide, leukocyte inhibitory factor, LUCT, lung carcinoma-derived chemotaxin, LYNAP, lymphocyte-derived neutrophil-activating peptide, MDNAP, monocyte-derived neutrophil-activating peptide, MDNCF, monocyte-derived neutrophil chemotactic factor, MOC, monocyte-derived chemotaxin, MONAP, monocyte-derived neutrophil-activating peptide, NAF, neutrophil-activating factor, NAP-1, neutrophil-activating protein-1, NCF, neutrophil chemotactic factor, NCP, neutrophil chemotactic protein, PLF, psoriatic leukotactic factor, TCF, T-cell chemotactic factor, TSG-1, Tumor necrosis factor-stimulated gene sequence-1) (De Sanctis et al, 1997; Mainiero et al, 2000; Mariani et al, 2002; Marti et al, 2002; Robertson, 2002; Saito et al, 1994; Li et al, 2009; El-Shazly and Lefebvre, 2011; Montaldo E et al, 2012)
IL8 (interleukin-8, SCYB8, 3-10C, 9E3, ANAP, anionic neutrophil-activating peptide, Chemotaxin, CEF-4, CT/IL8, CXCL8, CXC chemokine ligand 8, chemokine (C-X-C motif) ligand 8, EDNAP, endothelial-derived neutrophil-activating peptide, EMF-1, embryo fibroblast protein 1, Emoctakin, ENAP, Endothelial cell neutrophil-activating peptide, FDNAP, Fibroblast-derived neutrophil-activating peptide, FINAP, fibroblast-derived neutrophil-activating protein, GCF, granulocyte chemotactic factor, GCP, granulocyte chemotactic peptide, LAI, leukocyte adhesion inhibitor, LCF, lymphocyte chemotactic factors, LDNAP, leukocyte-derived neutrophil-activating peptide, leukocyte inhibitory factor, LUCT, lung carcinoma-derived chemotaxin, LYNAP, lymphocyte-derived neutrophil-activating peptide, MDNAP, monocyte-derived neutrophil-activating peptide, MDNCF, monocyte-derived neutrophil chemotactic factor, MOC, monocyte-derived chemotaxin, MONAP, monocyte-derived neutrophil-activating peptide, NAF, neutrophil-activating factor, NAP-1, neutrophil-activating protein-1, NCF, neutrophil chemotactic factor, NCP, neutrophil chemotactic protein, PLF, psoriatic leukotactic factor, TCF, T-cell chemotactic factor, TSG-1, Tumor necrosis factor-stimulated gene sequence-1) receptors (IL8RA, IL8R-alpha, interleukin-8 receptor-alpha; interleukin-8 receptor type A, IL8R1, IL8 receptor-1, interleukin-8 receptor type 1, CMKAR1, chemokine-alpha receptor 1, CXCR1, CD181, IL8RB, IL8R-beta, interleukin-8 receptor-beta; interleukin-8 receptor type B, IL8R2, IL8 receptor-2, interleukin-8 receptor type 2, CMKAR2, chemokine-alpha receptor 2, CXCR2, CD182) (al-Aoukaty et al, 1995; Mariani et al, 2002; Morohashi et al, 1995; Sebok et al, 1993; Inngjerdingen et al, 2001; Robertson, 2002; Ottaviani et al, 2006; Berahovich et al, 2006)
IL10 (interleukin-10, B-TCGF, B-cell derived T-cell growth factor, CSIF, cytokine synthesis inhibitory factor, TGIF, T-cell growth inhibitory factor) (Eriksson et al, 2004; Fehniger et al, 1999; Lidstrom et al, 2003; Maasho et al, 2000; Mehrotra et al, 1998; Vigano et al, 2001)
IL10 (interleukin-10, B-TCGF, B-cell derived T-cell growth factor, CSIF, cytokine synthesis inhibitory factor, TGIF, T-cell growth inhibitory factor) receptors (IL10R, IL10R1, IL10RA, IL10 receptor-alpha, IL10R-alpha, interleukin-10 receptor-alpha; interleukin-10 receptor, CD210, CD210a, CDw210a; IL10R2, IL10RB, IL10R-beta, IL10 receptor-beta, interleukin-10 receptor-beta, CRF2-4, cytokine receptor family 2 member 4, CRFB4; CDw210b) (Bluman et al, 1996; Cai et al, 1999; Carson et al, 1995; Frey et al, 1998; Shibata et al, 1998; Warren et al, 1995; Wolk et al, 2002)
IL12 (IL12A, IL12-alpha IL12B, IL12-beta, IL12-p35, IL12-p40, IL12-p70, Interleukin-12, Interleukin-12A, Interleukin-12B, CLMF, cytotoxic lymphocyte maturation factor, NKSF, natural killer cell stimulatory factor, NKSF1, natural killer cell stimulatory factor-1, NKSF2, natural killer cell stimulatory factor-2, TcMF, CTL maturation factor, TSF, T-cell stimulating factor) receptors (IL12RB1, IL12R-beta-1; interleukin-12 receptor-beta-1, IL12R, interleukin-12 receptor, IL12RB, IL12R-beta, interleukin-12 receptor-beta, CD212; IL12RB2, interleukin-12 receptor-beta-2; IL12R-beta-2) (Allavena et al, 1994; Alli and Khar, 2004; Bluman et al, 1996; Bohn and Autenrieth, 2000; Bonnema et al, 1994; Bream et al, 2003; Chakir et al, 2000; Deniz et al, 1999; Eriksson et al, 2004; Fehniger et al, 1999; Frey et al, 1998; Hunter et al, 1995; Johansson et al, 2004; Jyothi and Khar, 2000; Kataoka et al, 2005; Lauwerys et al, 1999; Lin et al, 2000; Marcenaro et al, 2005; Naume et al, 1993; Papadakis et al, 2004; Rabinowich et al, 1993; Wang et al, 2000; Warren et al, 1995; Sawaki et al, 2007; Alcon et al, 2009; Zhang et al, 2008; Lund H et al, 2012)
IL13 (Interleukin-13, NC30, P600) (Deniz et al, 1999; Hoshino et al, 1999; Loza et al, 2002; McDermott et al, 2005; Gao N et al, 2006)
IL15 (Interleukin-15, IL-T, Interleukin T) receptors (IL15RA, IL15R-alpha, CD215) (Allavena et al, 1997; Bluman et al, 1996; Carson et al, 1994, 1995; Choi et al, 2004; Cooper et al, 2002; Dann et al, 2005; de Rham et al, 2007; d'Ettorre et al, 2006; Eriksson et al, 2004; Fehniger et al, 1999; Frey et al, 1998; Gays et al, 2005; Grund et al, 2005; Kawamura et al, 2003; Kogure et al, 2002; Lin et al, 2000; Lum et al, 2004; Obata-Onai et al, 2002; Sechler et al, 2004; Verma et al, 2000; Zhang et al, 2008; Szczepanski et al, 2010; El-Shazly and Lefebvre, 2011; Lund H et al, 2012)
IL18 (interleukin-18, IGIF, IFN-gamma inducing factor, IL1-gamma, IL1F4, IL1 family member 4, Iboctadekin) receptors (IL18R1, interleukin-18 receptor-1, IL18R-alpha, IL18RA, interleukin-18 receptor-alpha, IL1Rrp, IL1 receptor-related protein, IL1R5, Interleukin-1 receptor 5, IL1 receptor R5, CD218a, CDw218a) (Born et al, 2000; Cai et al, 1999; Fehniger et al, 1999; Hayashi et al, 2003; Ishida et al, 2004; Johansson et al, 2004; Kataoka et al, 2005; Kawakami et al, 2000; Lauwerys et al, 1999; Micallef et al, 1997; Papadakis et al, 2004; Walker et al, 1999; Alcon et al, 2009; Dybkaer et al, 2007; Bellora F et al, 2012)
IL20 (interleukin-20, Zcyto10; IL10D, interleukin-10D) receptors (IL20RA, interleukin-20 receptor-alpha, IL20R-alpha, IL20R1, IL20 receptor-1, CRF2-8, cytokine receptor family 2 member 8, ZcytoR7; IL20RB, interleukin-20 receptor-beta, IL20R-beta, IL20R2, IL20 receptor-2, DIRS1) (Wolk et al, 2002)
IL21 (interleukin-21) receptors (IL21R, IL21R-alpha, IL21RA, IL21 receptor-alpha, interleukin-21 receptor, interleukin-21 receptor-alpha, NILR, novel interleukin receptor, CD360) (Burgess SJ et al, 2006; de Rham et al, 2007; Kasaian et al, 2002; Mehta et al, 2003; Perez et al, 2006; Strengell et al, 2004; Brady et al, 2004; Gays et al, 2005; Vollmer et al, 2005; Wang et al, 2003; Yoon et al, 2008; Frederiksen et al, 2008; Bonanno et al, 2009; Iannello et al, 2010)
IL22 (Interleukin-22, IL-TIF, IL10-related T-cell derived inducible factor) (Wolk et al, 2002; Hughes et al, 2009; Cella et al, 2009)
IL22 (Interleukin-22, IL-TIF, IL10-related T-cell derived inducible factor) (Cella et al, 2009; Wolk et al, 2002)
IL23 (interleukin-23, IL12B, IL12-p40, IL23-p40, p19, IL23-p19, IL23A, SGRF, IL6 G-CSF related factor) receptors (Zhang et al, 2003; van de Wetering et al, 2009)
IL24 (interleukin-24, ST16, suppression of tumorigenicity-16, MDA-7, melanoma differentiation-associated gene 7, mob-5, C49a, FISP, IL4 induced secreted protein) (Poindexter et al, 2005)
IL26 (interleukin-26, AK155) (Wolk et al, 2002)
IL27 (interleukin-27, EBI-3, EBV induced gene-3, IL27A, IL27-alpha, interleukin-27-alpha, IL27B; IL27-beta, interleukin-27-beta, p28, IL27p28, IL30, interleukin-30) receptors (IL27RA, IL27 receptor-alpha, interleukin-27 receptor-alpha, IL27R, IL27R-alpha, CRL1, Cytokine receptor-like 1, WSX-1, TCCR, T-cell cytokine receptor, ZCytoR1) (Zhang et al, 2003; Dybkaer et al, 2007; Matsui M et al, 2009)
IL32 (interleukin-32, IL32-alpha, IL32-beta, IL32-delta, IL32-epsilon, IL32-gamma, IL32-zeta, NK4, natural killer cell transcript 4, TAIF, tumor necrosis factor alpha-inducing factor, TAIFa, TAIF-alpha, TAIFb, TAIFc, TAIF-beta, TAIFd, TAIF-delta) (Kim et al, 2005; Dahl et al, 1992; Goda et al, 2006)
IL33 (interleukin-33, NFHEV, nuclear factor from high endothelial venules, C9orf26, chromosome 9 open reading frame 26, DVS27) receptors (IL33R, IL1RL1, IL1 receptor-like-1, IL1R4, interleukin-1 receptor 4, IL1 receptor R4, T1, T1/ST2, ST2, ST2L, Fit-1, fos-induced transcript-1, Ly84, lymphocyte antigen 84, DER4, delayed early response gene 4) (Bourgeois E et al, 2009; Smithgall et al, 2008)
IL37 (interleukin-37, IL1F7, IL1 family member 7, Interleukin-1 family member 7, IL1F7b, Interleukin-1 family member 7b, IL1H, IL1HLa, IL1HL, IL1HS, IL1H4, IL1 homolog-4, IL1-zeta, FIL1-zeta, Family of IL1-zeta, FIL1Z, IL1RP1, IL1-related protein-1) (cited as unpublished in Boraschi et al, 2011)

KIR3DL1 (Killer cell immunoglobulin-like receptor 3DL1, NKAT3, NK-associated transcript-3, NKB1, CL11, AMB11, KIRL1, KIR-like-1, DX9 antigen) (Morvan et al, 2009)
KLRC3 (killer cell lectin-like receptor subfamily C member 3, NKG2E) (Dybkaer et al, 2007)

LCRF (luminal CCK-releasing factor, luminal cholecystokinin releasing factor, diazepam binding inhibitor, DBI, endozepine, acyl-CoA-binding protein, ACBP, cholecystokinin releasing peptide, CCK-RP) (Rocca et al, 1993)
leptin (ob, ob/ob, obese protein, obesity factor, Metreleptin) receptors (LEPR, OBR, CD295, db, db/db, fatty, fa, fa/fa) (Nave et al, 2008)
LIF (leukemia inhibitory factor; myeloid leukemia inhibitory factor, ABAE cell growth-inhibitory activity; CDF, cholinergic differentiation factor, CNDF, cholinergic neuronal differentiation factor, D-Factor, differentiation stimulating factor, DIA, differentiation inhibiting activity, DIF, differentiation inducing factor, DRF, Differentiation-retarding factor, ES cell growth factor, ESCGF, embryonic stem cell growth factor, GATS, growth stimulatory activity for TS1 cells, HILDA, human interleukin for Da cells, HSF-2, hepatocyte stimulating factor-2, HSF-3, hepatocyte stimulating factor-3, Lipoprotein lipase inhibitor, M1 differentiation inducing activity, MCGEF, mast cell growth-enhancing factor, MLPLI, melanoma-derived lipoprotein lipase inhibitor, OAF, osteoclast activating factor) (De Sanctis et al, 1997; Saito et al, 1993; Cella et al, 2009)
LIGHT (TNFSF14, TNF ligand superfamily member 14, HVEM ligand, HVEM-L, Herpesvirus entry mediator ligand, CD258) (Cohavy et al, 2005)
Ly6C (lymphocyte antigen 6C, Ly6C1, lymphocyte antigen 6C1) (Manoussaka et al, 1998; Sato N et al, 1996)
lymphotoxin-beta (LT-beta, LTB, TNFSF3, TNF ligand superfamily member 3, TNF C, tumor necrosis factor C) (Kashii et al, 1999)

MAFA (Mast-cell-function-associated antigen, MAFA-L, MAFA-like, CLEC15A, C-type lectin domain family 15 member A, KLRG1, killer cell lectin-like receptor G1) (Butcher et al, 1998)
M-CSF (macrophage colony stimulating factor, CSF-1, colony stimulating factor-1, CSF-HU, Urinary colony stimulating factor, MGF, macrophage growth factor, MGI-1M, macrophage-granulocyte inducer, op, osteopetrotic, toothless, tl, Lanimostim) (Aste-Amezaga et al, 1994; Cuturi et al, 1989; Saito et al, 1993)
mer (MERTK, eyk, East Lansing Tyrosine Kinase, nyk, NCAM-related tyrosine kinase, RP38, retinitis pigmentosa type 38, tyro12, tyrosine-protein kinase 12) (Behrens et al, 2003; Caraux et al, 2006)
Met-Enkephalin (Met5-Enkephalin, MENK, OGF, opioid growth factor) receptors (Zhong et al, 1996)
MMP-2 (matrix metalloproteinase-2, EC3.4.24.24, 70 kDa gelatinase, 72 kDa gelatinase, 72 kDa metalloproteinase, collagenase type 4, collagenase type 4A, 72 kDa type IV collagenase, Gelatinase 72 kDa, Gelatinase A, Type IV collagenase, Type IVA collagenase, neutrophil gelatinase) (Albertsson et al, 2000; Ishida et al, 2004; Kim et al, 2000; Kitson et al, 2000; Edsparr et al, 2009)
MMP-3 (matrix metalloproteinase-3, stromelysin-1, STMY1, STR1, SL-1, transin, transin-1, collagenase activating protein, procollagenase activator, proteoglycanase) (Kim et al, 2000)
MMP-7 (matrix metalloproteinase-7, matrilysin, Matrilysin-1, PUMP, punctuated metalloproteinase, pump-1, putative metalloproteinase-1, matrin, EC3.4.24.23) (Kim et al, 2000)
MMP-9 (matrix metalloproteinase-9, EC3.4.24.35, gelatinase B, 92 kDa gelatinase, 92 kDa type IV collagenase, or PMNL gelatinase, polymorphonuclear leukocyte gelatinase, gelatinase type IV-B, collagenase type 5, collagenase-5, CL-5) (Albertsson et al, 2000; Kim et al, 2000; Kitson et al, 2000; Edsparr et al, 2009)
MMP-10 (matrix metalloproteinase-10, stromelysin-2, STMY2, SL-2, ST-2, transin-2, EC3.4.24.22) (Kim et al, 2000)
MMP-11 (matrix metalloproteinase-11, stromelysin-3, STMY3, SL-3, ST-3) (Kim et al, 2000)
MMP-13 (matrix metalloproteinase-13, Collagenase-3, CLG3, CL-3) (Kim et al, 2000; Edsparr et al, 2009)
MMP-14 (matrix metalloproteinase-14, MT1-MMP, Membrane-type matrix metalloproteinase-1, MT-MMP-1, MMP-X1) (Albertsson et al, 2000; Ishida et al, 2004; Kim et al, 2000; Edsparr et al, 2009)
MMP-15 (matrix metalloproteinase-15, MT2-MMP, Membrane-type matrix metalloproteinase-2, MT-MMP-2) (Kim et al, 2000)
MMP-16 (matrix metalloproteinase-16, MT3-MMP, Membrane-type matrix metalloproteinase-3, MT-MMP-3, C8orf57, chromosome 8 open reading frame 57) (Edsparr et al, 2009
MMP-25 (matrix metalloproteinase-25, Membrane-type matrix metalloproteinase-6, MT6-MMP, MT-MMP-6, leukolysin, MMPL1, matrix metalloproteinase-like 1, matrix metallopeptidase-like 1) (Edsparr et al, 2009)

NELL-2 (NEL-like 2, neural epidermal growth factor-like 2, NEL-like protein 2, NRP2, Nel-related protein 2) (Oyasu et al, 2000; Kuroda et al, 1999)
neuropeptide Y (NPY, Y Neuropeptide) (Vermijlen et al, 2004)
NKG2C (KLRC2, killer cell lectin-like receptor subfamily C member 2, CD159c) (Vermijlen et al, 2004)
NKG2D (NK cell receptor D, KLR KLRK1, killer cell lectin-like receptor subfamily K member 1, KLRC4, killer cell lectin-like receptor subfamily C member 4, NKR-P2, natural killer cell receptor P2, NK-cell receptor P2, NK-cell receptor protein-2, CD314) (Berg et al, 1998; Bryceson et al, 2006; Ho et al, 2002; Ogasawara et al, 2003; Regunathan et al, 2005; Sutherland et al, 2002; Vermijlen et al, 2004; Zompi et al, 2003; DeHart et al, 2005; de Rham et al, 2007; Peraldi et al, 2009; Fan et al, 2008; Crane et al, 2010; Steigerwald et al 2009; Bonanno et al, 2009; Sun C et al, 2012)
NKG7 (natural killer cell group 7 sequence, natural killer cell protein 7, GIG1, G-CSF-induced gene 1 protein) (Turman et al, 1993; Mori et al, 1998)
NKLAM (NK lytic-associated molecule, IBRDC3, IBR domain containing protein 3, RNF19B, ring finger protein 19B) (Kozlowski et al, 1999)
NK-lysin (NKL) (Andersson et al, 1995)
NK-released peptide (Angchaisuksiri et al, 2002)
nm23 (nonmetastatic gene 23, p19/nm23, EC2.7.4.6, NDP kinase, nucleoside diphosphate kinase, NDP kinase A, NDPKA, Nucleoside diphosphate kinase A, nm23A, NDP kinase B, NDPKB, Nucleoside diphosphate kinase B, nm23B, NME1, nonmetastatic cells 1, NME2, nonmetastatic cells 2, Metastasis inhibition factor, nm23-H1, GADD, Granzyme A-activated DNase, I factor, PuF, nm23-H2) (Ohtsuki et al, 1985)
NOD1 (Nucleotide-binding oligomerization domain protein 1, CARD4, caspase recruitment domain-containing protein-4, NLRC1, NLR family, CARD domain containing 1) (Fu Qiu et al, 2011)
NOD2 (Nucleotide-binding oligomerization domain protein 2, CARD15, caspase recruitment domain-containing protein-15, NLRC2, NLR family, CARD domain containing 2, IBD1, inflammatory bowel disease 1, BLAU, CLR16.3) (Fu Qiu et al, 2011)
Notch-1 (Notch, Motch, Motch A, TAN-1, translocation-associated notch homolog-1) (DeHart et al, 2005)

osteopontin (OPN, OP, Osp, 2ar, 44 kDa bone phosphoprotein, 66 kDa bone phosphoprotein, bone sialoprotein, bone sialoprotein-1, BSP, BSP1, BSPI, Calcium oxalate crystal growth inhibitor protein, Eta-1, early T-lymphocyte activation protein 1, Nephropontin, Spp-1, Secreted Phosphoprotein-1, transformation-related phosphoprotein, tumor-secreted phosphoprotein, urinary stone protein, Uropontin) (Pollack et al, 1994)

p28/CLF (IL27p28, IL27A, IL27-alpha, interleukin-27-alpha, IL30, interleukin-30, CLF-1, Cytokine-like factor-1, CRLF-1, cytokine receptor-like factor-1, CRLM-3, cytokine receptor-like molecule-3, NR6, CISS1, Cold-induced sweating syndrome, ZcytoR5) receptors (Crabe et al, 2009)
PDCD1 (programmed cell death-1, PD-1, programmed death-1, Ly101, CD279) (Norris S et al, 2012)
PDGF (platelet-derived growth factor, PDGF-1, PDGF-2, PDGF-A, PDGF-AA, PDGF-B, PDGF-BB, FDGF, fibroblast-derived growth factor, GDGF, glioma-derived growth factor-1, GDGF-2, glioma-derived growth factor-2, GSM, Glucocorticoid-suppressible mitogenic activity, MDF, mesangial cell proliferating factor, MDGF, monocyte-derived growth factor, OBIF, osteoblastogenesis inhibitory factor, ODGF, osteosarcoma-derived growth factor, T47D factor) receptors (PDGFR, PDGFR1, PDGFR2, PDGFRA, PDGFR-alpha, PDGFRB, PDGFR-beta, PDGF receptor, PDGF receptor-1, PDGF receptor-2, PDGF receptor-alpha, PDGF receptor-beta; patch; CD140a, CD140b, JTK12) (Vermijlen et al, 2004)
perforin-1 (pore-forming protein-1, perforin, pore-forming protein, PFP, PFN, PRF1, PFN1) (Briard et al, 2002; Clement et al, 1990; Dalle et al, 2005; DeBlaker-Hohe et al, 1995; DeHart et al, 2005; Fan et al, 2008; Mori et al, 1998; Obata-Onai et al, 2002; Rukavina et al, 1998; Salcedo et al, 1993; Sayers et al, 2001)
PI9 (proteinase inhibitor-9, Serpin B9, CAP3, cytoplasmic antiproteinase 3, serine protease inhibitor-6, SPI-6) (Horie et al, 2005; Sun et al, 1996; Vermijlen et al (2002)
PlGF (placenta growth factor, Placental growth factor, PGF, PlGF-1, placenta growth factor-1, PlGF-2, placenta growth factor-2) (Li XF et al, 2001)
PLP-A (Prolactin-like protein A, Placental prolactin-like protein A, PRL-like protein A, PRLPA) receptors (Ain et al, 2003; Muller et al, 1999)
prolactin (PRL, lactogenic hormone, lactotropin, lactotropic hormone, mammotropin, mammotropic hormone, luteotropic hormone, LTH, luteotropin) receptors (PRLR) (Chakraborty et al, 1996; Chambers et al, 1995; Sun et al, 2004, 2002-2003)
PYPAF1 (Pyrin-containing APAF-1-like protein 1, NLRP3, NLR family, pyrin-domain containing 3, NALP3, NACHT-LRR-PYD-containing protein-3, CIS1, CIAS1, cold-induced auto-inflammatory syndrome, Cryopyrin, CLR1.1) (Fu Qiu et al, 2011)

SCF (stem cell factor, HLGF-1, hemolymphopoietic growth factor-1), kit ligand, KITL, KITLG, Mast/stem cell growth factor, MGF, mast cell growth factor, SLF, steel factor) receptors (kit, SCFR, CD117) (Carson et al, 1994; Colucci and Di Santo, 2000; DeHart et al, 2005; Fehniger et al, 1997; Matos et al, 1993; Umekage et al, 1998; Vermijlen et al, 2004)
secretogranin (Mocellin et al, 2004)
Semaphorin 4D (SEMA4D, Semaphorin J, SEMAJ, CD100, M-sema G, collapsin-4, coll-4, BB18, A8, GR3, C9orf164, chromosome 9 open reading frame 164) (Elhabazi et al, 1997; Mizrahi et al, 2007)
Semaphorin 4D (SEMA4D, Semaphorin J, SEMAJ, CD100, M-sema G, collapsin-4, coll-4, BB18, A8, GR3, C9orf164, chromosome 9 open reading frame 164) receptors (CD72) (Alcon et al, 2009)
serglycin (SRGN, PRG1, PRG, PPG, platelet proteoglycan protein core) (Toyama-Sorimachi et al, 1997; Fadnes B et al, 2012)
SIGLEC-7 (sialic acid binding immunoglobulin-like lectin 7, AIRM1, adhesion inhibitory receptor molecule 1, p75/AIRM1, QA79 membrane protein, D-SIGLEC, CDw328, CD328) (Ito et al, 2001)
SIGLEC-9 (sialic acid binding immunoglobulin-like lectin 9, OBBP-like, Ob binding protein-like, CDw329, CD329, FOAP-9, SIGLEC-E) (Zhang et al, 2004)
SIGLEC-10 (sialic acid binding immunoglobulin-like lectin 10, CD330, SLG2, SIGLEC-like gene 2) (Munday et al, 2001)
SLAMF6 (signaling lymphocyte activation molecule family member 6, SLAM family member 6, NTB-A, NK-cell T-cell B-cell antigen, NK-T-B antigen, Ly108, KALI, SF2000, SLAM family 2000, CD352) (Bottino et al, 2001; Eissmann and Watzl, 2006; Flaig et al, 2004; Stark and Watzl, 2006)
SLURP-2 (Secreted Ly-6/uPAR-related protein 2; secreted Ly-6/PLAUR domain-containing protein 2, GC26, LYNX1, Ly-6/neurotoxin-like protein 1) (Kawashima et al, 2007)
STAT1 (signal transducer and activator of transcription-1, STAT1-alpha, STAT1-beta, p91, Stat91, p84) (Matsui M et al, 2009)
STAT3 (signal transducer and activator of transcription-3, APRF, acute phase response factor, STAT3-alpha, STAT3-beta, STAT3-gamma, STAT3-delta) (Matsui M et al, 2009)
STAT4 (signal transducer and activator of transcription-4) (Miyagi T et al, 2010)

TGF-beta (transforming growth factor-beta, TGFB, B-TGF, Aqueous humor lymphocyte inhibitory activity, DIF, differentiation-inhibiting factor, EGI, epithelial cell-specific growth inhibitor; epithelial growth inhibitor, EIF, Epstein-Barr virus inducing factor, Epithelial cell growth inhibiting factor, G-TsF, glioma-derived T-cell suppressor factor, MDGF, milk-derived growth factor, MGF, milk growth factor, Polyergin, Simian BSC-1 cell growth inhibitor, SP factor, TCGF, transformed cell growth factor, TGI, tissue-derived growth inhibitor, TIF-1, tumor inducing factor-1) (Gray et al, 1998)
TGF-beta (transforming growth factor-beta, TGFB, B-TGF, Aqueous humor lymphocyte inhibitory activity, DIF, differentiation-inhibiting factor, EGI, epithelial cell-specific growth inhibitor; epithelial growth inhibitor, EIF, Epstein-Barr virus inducing factor, Epithelial cell growth inhibiting factor, G-TsF, glioma-derived T-cell suppressor factor, MDGF, milk-derived growth factor, MGF, milk growth factor, Polyergin, Simian BSC-1 cell growth inhibitor, SP factor, TCGF, transformed cell growth factor, TGI, tissue-derived growth inhibitor, TIF-1, tumor inducing factor-1) receptors (TGFBR1, TbetaRI, TbetaR1, transforming growth factor-beta receptor 1, TGF-beta receptor 1; TGF-beta receptor type 1, type 1 TGF-beta receptors, ALK5, Activin receptor-like kinase 5, activin A receptor type 2-like kinase, ACVRLK4, activin receptor-like kinase 4 ; TGFBR2, TbetaRII, TbetaR2, transforming growth factor-beta receptor 2, TGF-beta receptor 2, TGF-beta receptor type 2, type 1 TGF-beta receptors, MFS2, Marfan syndrome type 2) (Bellone et al, 1995; Eriksson et al, 2004; Frey et al, 1998; Hayashi et al, 2003; Hunter et al, 1995; Maghazachi and al-Aoukaty, 1993; Rook et al, 2000; Saito et al, 1993; Trotta et al, 2008; Crane et al, 2010)
TGF-beta-1 (TGFB1, transforming growth factor-beta-1, CIF-A, cartilage inducing factor A, ISF, immunosuppressive factor, MGF-b, milk growth factor, PDGI, platelet-derived endothelial cell growth inhibitor) receptors (TGFBR1, TbetaRI, TbetaR1, transforming growth factor-beta receptor 1, TGF-beta receptor 1; TGF-beta receptor type 1, type 1 TGF-beta receptors, ALK5, Activin receptor-like kinase 5, activin A receptor type 2-like kinase, ACVRLK4, activin receptor-like kinase 4 ; TGFBR2, TbetaRII, TbetaR2, transforming growth factor-beta receptor 2, TGF-beta receptor 2, TGF-beta receptor type 2, type 1 TGF-beta receptors, MFS2, Marfan syndrome type 2) (Sun C et al, 2012)
Thrombin (coagulation factor-2, factor IIa) receptors (Vermijlen et al, 2004)
thymosin-alpha-1 (Prothymosin-alpha, PTMA, Thymalfasin, Zadaxin) receptors (Umeda et al, 1983; Favalli et al, 1989; Sderrate et al, 1987)
thymosin-beta-4 (TMSB4, TMSB4X, Tb4, Tbeta-4, 6-26, Fx, PTMB4, THYB4) receptors (Lee et al, 2009)
TIA-1 (T-cell restricted intracellular antigen-1, cytotoxic granule-associated RNA-binding protein) (Mocellin et al, 2004)
TIGIT (T-cell immunoreceptor with Ig and ITIM domain, WUCAM, Washington University Cell Adhesion Molecule, Vstm3 [V-set and transmembrane domain containing 3, VSIG9, V-set and immunoglobulin domain containing 9) (Yu et al, 2009)
Tim-1 (T-cell immunoglobulin and mucin domain-containing protein 1, T-cell membrane protein 1, TIMD1, HAVCR1, hepatitis A virus cellular receptor 1, HAVCR, hepatitis A virus cellular receptor, HAV receptor, KIM-1, Kidney injury molecule 1, Tapr, T-cell and airway phenotype regulator) (Khademi et al, 2004)
Tim-3 (T-cell immunoglobulin and mucin domain-containing protein 3; T-cell membrane protein 3, T-cell immunoglobulin mucin 3, T-cell Ig mucin 3, Timd3, HAVCR2, hepatitis A virus cellular receptor 2) (Khademi et al, 2004; Hou N et al, 2012; Gleason et al, 2012; Ju Y et al, 2009; Ndhlovu et al, 2012; Hou N et al, 2012)
TIMP-1 (tissue inhibitor of metalloproteinases-1, TIMP metallopeptidase inhibitor 1, TIMP, tissue inhibitor of metalloproteinases, HCI, human collagenase inhibitor, CLGI, 3/10, 16C8, Fibroblast elongation factor, fibroblast collagenase inhibitor, B1 anticollagenase, Beta-1 anticollagenase, EPA, erythroid promoting activity, embryogenin-1, TPA-S1, TPA-induced protein S1) (Albertsson et al, 2000; Kim et al, 2000)
TIMP-2 (tissue inhibitor of metalloproteinases-2, TIMP metallopeptidase inhibitor 2, CSC-21K, MI, CHIAMP, Chondrocyte-derived inhibitor of angiogenesis and metalloproteinase activity) (Kim et al, 2000)
TLR-1 (Toll-like receptor-1, rsc786, randomly sequenced cDNA 786, TIL, Toll-interleukin-1 receptor-like, CD281) (Muzio et al, 2000)
TLR-2 (Toll-like receptor-2, TIL-4, Toll-interleukin-1 receptor-like-4, Ly105, lymphocyte antigen 105, CD282) (Becker et al, 2003; Chalifour et al, 2004; Saikh et al, 2003; Sawaki et al, 2007)
TLR-3 (Toll-like receptor-3, CD283) (Pisegna et al, 2004; Saikh et al, 2003; Sivori et al, 2004; Neves et al, 2009; Fu Qiu et al, 2011; Bao SH et al, 2012)
TLR-4 (Toll-like receptor-4, human Toll, TOLL, Ly87, Rasl2-8, CD284) (Saikh et al, 2003; Sawaki et al, 2007)
TLR-5 [Toll-like receptor-5, TIL-3, Toll-interleukin-1 receptor-like-3) (Chalifour et al, 2004)
TLR-7 (Toll-like receptor-7) (Hart et al, 2005; Sawaki et al, 2007; Fu Qiu et al, 2011)
TLR-8 (Toll-like receptor-8, CD288) (Hart et al, 2005)
TLR-9 (Toll-like receptor-9, A6RP, A6-related protein, CD289) (Roda et al, 2005; Sivori et al, 2004; Neves et al, 2009; Fu Qiu et al, 2011)
TNF-alpha (tumor necrosis factor-alpha, TNFSF2, TNF ligand superfamily member 2, Cachectin, CF, cytotoxic fac

or, CTX, cytotoxin, DIF, differentiation inducing factor, EP, endogenous pyrogens, Hemorrhagic factor, Macrophage-derived cytotoxic factor, J774-derived cytotoxic factor, MCF, macrophage cytotoxic factor, MCT, macrophage cytotoxin, MD-FGF, monocyte-derived fibroblast growth factor, PCF, peritoneal cytotoxic factor, RCF, Released cytotoxic factor) (Aramburu et al, 1990, 1993; Aste-Amezaga et al, 1994; Barakonyi et al, 2004; Caron et al, 1999; De Sanctis et al, 1997; Fehniger et al, 1999; Jewett and Bonavida, 1995; Jewett et al, 2006; Kashii et al, 1999; Kim and Yokoyama, 1998; Manoussaka et al, 1997; Melero et al, 1993; Mori et al, 1998; Saito et al, 1993; Li et al, 2009; Steigerwald et al 2009)
TNF-alpha (tumor necrosis factor-alpha, TNFSF2, TNF ligand superfamily member 2, Cachectin, CF, cytotoxic factor, CTX, cytotoxin, DIF, differentiation inducing factor, EP, endogenous pyrogens, Hemorrhagic factor, Macrophage-derived cytotoxic factor, J774-derived cytotoxic factor, MCF, macrophage cytotoxic factor, MCT, macrophage cytotoxin, MD-FGF, monocyte-derived fibroblast growth factor, PCF, peritoneal cytotoxic factor, RCF, Released cytotoxic factor) receptors (CD120a, TNFRSF1A, TNF receptor superfamily member 1A, FPF, TNFAR, TNFR, TNFR1, TNFR55, TNFR60, TNFR-alpha, TNF receptor 1; CD120b, TNFRSF1B, TNF receptor superfamily member 1B, p75TNFR, TNFR2, TNFR75, TNFR80, TNFR-beta) (Bluman et al, 1996; Mason et al, 1995; Naume et al, 1993; Ostensen et al, 1987)
TNF-beta (tumor necrosis factor-beta, TNFB, Coley's toxin, LT, lymphotoxin, lymphotoxin-alpha, LT-alpha, LTA, Necrosin, NKCF, natural killer cytotoxic factor, NK-CIA, Natural killer colony-inhibiting activity, TNFSF1, TNF ligand superfamily member 1) (Kashii et al, 1999)
TRAIL (TNF-related apoptosis inducing ligand, APO-2 ligand, APO-2L, TL2, TNF-like-2, TNF ligand superfamily member 10, TNFSF10, Ly81, CD253) (Kashii et al, 1999; Johnsen et al, 1999; Kayagaki et al, 1999; Takeda et al, 2005; Zamai et al, 1998; Dybkaer et al, 2007; Yamamoto et al, 2004)
transferrin (TRF, DF-77, GPBP, granulocyte/pollen-binding protein, Lung-derived growth factor) receptors (CD71, TFR, TFR1, TRFR, TFRC, OKT9, T9, OX26) (Perussia et al, 1985; Rabinowich et al, 1993)
TSLP (thymic stromal derived lymphopoietin, Thymic stromal lymphopoietin) receptors (CRLF-2, cytokine receptor-like factor-2, Ly114, CRL2) (Trnroos H et al, 2007)
tyro3 (tyrosine-protein kinase 3, brt, dtk, rse, sky, tif) (Caraux et al, 2006)

urotensin-2 (UTS-2, UTN-2, U2) receptors (Segain et al, 2007)

VEGF-A (Vascular endothelial growth factor A; VEGF-1, vascular endothelial growth factor-1, VEGF, vascular endothelial growth factor; vasculo-endothelial growth factor, VEG/PF, vascular endothelial growth factor/vascular permeability factor, GD-VEGF, glioma-derived vascular endothelial growth factor, VAS, Vasculotropin, Vascular endothelial cell proliferation factor; VPF, vascular permeability factor, Mouse sarcoma 180-derived growth factor; FSdGF, Folliculo stellate cell-derived growth factor) receptors (Chen et al, 2002; Mocellin et al, 2004)
VEGF-B (vascular endothelial growth factor B, VEGF-B(167), VEGF-B(186), VRF, VEGF related factor, VRP, VEGF related protein) (Chen et al, 2002)
VEGF-C (vascular endothelial growth factor C, VEGF-2, Vascular endothelial growth factor-2, flt-4 ligand, flt-4L) (Li XF et al, 2001; Zhang X et al, 2012)
VEGI (vascular endothelial growth inhibitor, VEGI-174, TNFSF15, TNF ligand superfamily member 15, TL1, TL1A, TNF-like-1) (Papadakis et al, 2004)

XCL1 (chemokine C motif ligand-1, CL1, lymphotactin, Ltn, Lptn, SCM-1-alpha, Single C motif-1-alpha, ATAC, activation induced T-cell derived and chemokine related, SCYC1) (Dorner et al, 2004; Hedcrick et al, 1997; Hennemann et al, 1999; Robertson, 2002; Yamazaki C et al, 2010)
XCL1 (chemokine C motif ligand-1, CL1, lymphotactin, Ltn, Lptn, SCM-1-alpha, Single C motif-1-alpha, ATAC, activation induced T-cell derived and chemokine related, SCYC1) receptors (Giancarion et al, 1996; Hedcrick et al, 1997; Maghazachi et al, 1997; Yamazaki C et al, 2010)

ZAP70 (zeta chain-associated protein kinase 70 kDa, Zeta-associated protein 70) (Chan et al, 1992)

For related information of interest see also: Cell types, Cell lines in Cytokine Research, Cell culture. For other entries pertaining to hematopoiesis see also the Hematology Dictionary section of this encyclopedia.


Copyright 2012 by H IBELGAUFTS. All rights reserved.
ENTRY LAST MODIFIED: April 2012



 

See REFERENCES for entry NK-cells.

Click BACKLINKS to see which COPE entries contain the term NK-cells .




COPE Homepage Top of Page


 
 
SUPPORT COPE | Santa Claus | Intro | Subdictionaries | New Entries | Contribute data | COPE Credentials
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Please inquire. COPE is looking for long-term support from a company appreciating and committed to communication biology

              Created, developed, and maintained by Prof Dr H Ibelgaufts              
About the author of COPE
  |    Contact COPE   |    postcard and stampware   |    Terms & Conditions


Access to COPE is free only for academic institutions and non-profit organizations.
OTHER USERS: must contact COPE and pay a site licence fee.

U L T R A   P O S S E   N E M O   O B L I G A T U R